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ABSTRACT
Mixed Lineage Leukemia (MLL) is a multidomain protein whose gene is
translocated in a subset of AML leukemias. Translocation of the MLL gene is present in
approximately five percent of adult acute leukemias and ten percent of pediatric
leukemias (Daser, A 2004, Look, A 1997, Huret, J 2001) Patients presenting in the clinic
at the time of diagnosis with an MLL fusion have been shown to respond poorly to
treatment and have a worse prognosis than matched wild type MLL patients (Rubnitz, J
1994, Rubnitz, J 1999). Novel therapies therefore are needed in order to more effectively
treat patients with MLL leukemias.
Cyclophilin33 (CYP33) has previously been shown to be a negative modulator of
MLL gene transactivation activity (Fair, K 2001, Anderson, M 2002). It has been well
established that for CYP33 to exert its repressive effects on MLL several events must
occur. CYP33 binds to the 3rd PHD (PHD3) finger of MLL and increases Histone
Deacacetylase1 (HDAC1) to the repression domain (RD) of MLL thereby reducing target
gene expression (Xia, Z 2003, Fair, K 2001, Anderson, M 2002). It has been
hypothesized that cis-trans prolyl isomerase activity is important for recruitment of
HDAC1 as increased CYP33 leads to increased HDAC1 at RD domain of MLL (Fair, K
2001, Xia, Z 2003, Chen, J 2008). In cells treated with the inhibitor, Cyclosporin A
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(CsA), CYP33 was not able to recruit HDAC1 to MLL (Koonce, M 2004). hPC2, BMI1
and CtBP also bind to the MLL repression domain, although the role these co-repressor
proteins play in suppression of MLL target gene activation has not been elucidated (Xia,
Z 2003). In this study, the co-repressor proteins (HDAC and BMI1) that bind to MLL
RD were examined to determine if CYP33 leads to the recruitment of HDAC1 and BMI1
to the RD of MLL. Also CYP33 PPIase activity was examined to determine if it is
essential for HDAC1 and BMI1 binding to MLL.
Once HDAC1 and BMI1 were established to bind to MLL in a PPIase dependent
manner, the chromatin modifications on the H3 histone tail, which are known substrates
of HDAC1, were examined to determine if the H3 Acetylation (Ac) changes in response
to CYP33 levels. H3Ac (H3K9Ac, H3K14Ac) and H3K27Ac are critical marks for
active gene transcription, while its counterpart H3 lysine 27 trimethylation (H3K27Me3)
is a mark for gene repression. It has been proposed that one of the main roles of
H3K27Ac is to block H3K27Me3 (Pasini, D 2010). This hypothesis was tested in MSA
cells, a thyroid carcinoma cell line, which showed robust decrease of CYP33 protein
upon knockdown by siRNA treatment and concomitant upregulation of MLL target
genes. Upon modulation of CYP33 in MSA cells, it is seen that H3K27Ac inversely
correlates with CYP33 expression levels. H3Ac increases upon knockdown of CYP33,
but does not show a reduction upon CYP33 overexpression in MSA cell line.
H3K27Me3 levels are low at MLL gene promoters in MSA cells and remain unchanged.
After studying the levels of H3Ac and H3K27Ac, HDAC1 and BMI1 recruitment
to the chromatin was examined to determine if HDAC1 and BMI1 recruitment to MLL
xii

target gene promoters occurs in a CYP33 dependent manner. Surprisingly no change was
seen upon CYP33 overexpression. A decrease of HDAC1 was seen at some MLL target
gene promoters upon knockdown of CYP33 by siRNA.
After knockdown of CYP33 in MSA cells, oscillations in MLL and MYC gene
expression levels were observed. This could be due to regulation of CYP33 expression
by a negative feedback loop. Many such regulatory networks exist in the cell. From
exploring the CYP33 that is bound to the chromatin, it is clear that CYP33 is located not
only at the promoters of MLL targets, but also at the promoter of housekeeping genes, βACTIN or GAPDH. Also CYP33 was found to bind to the promoters of MLL and CYP33,
suggesting that the oscillations could be due to a negative feedback loop.
CYP33 plays a role in the repression of MLL target genes by regulating the level
of HDAC1 and BMI1 recruitment to MLL, and subsequently the levels of H3Ac and
H3K27Ac. Understanding the role CYP33 plays in gene transcription leads to a better
knowledge of MLL mediated transactivation and may lead to new and novel therapies in
MLL leukemia.
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CHAPTER I
INTRODUCTION

Cancer is the leading cause of preventable death worldwide, and it is estimated
that 577,190 Americans will die from cancer in 2012 (Siegel R, 2012). Although this is a
discouraging number, many deaths have been prevented in the past decades due to the
development of better prophylactic screening and innovative treatments. Cancer is a
disease which arises from either hereditary genetic mutations or the effects of a variety of
factors found in the environment, such as ultraviolet and ionizing radiation, chemical
carcinogens, and viral insertions (Vogelstein B, 1993). Cancer is not caused by a single
event or genetic mutation, but is the product of multiple genetic mutations and epigenetic
changes often targeting several pathways (Farber E, 1984). It is a heterogeneous disease
arising in otherwise normal cells that sustain altered genetic information which is stored
in DNA (Marusyk A, 2010).
Cancers that arise within the blood system are termed hematopoietic
malignancies. Chromosomal translocations occur in hematopoietic malignancies leading
to the generation of fusion proteins with altered functions; along with point mutations
chromosomal translocations lead to cancer. Translocations occur when a double strand
break occurs in DNA followed by improper DNA repair in which two different
1
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Chromosomes fragments are erroneously joined. BCR-ABL and MLL fusions are well
known examples of chromosomal translocations (Rabbitts T, 1994). The MLL fusions
create a chimeric protein that drives cellular processes towards a malignant phenotype
(Fig. 1). Unlike other fusions that always partner with the same gene to lead to leukemic
transformation such as BCR-ABL, MLL has multiple translocation partners. The Nterminal gene sequence of MLL translocates to over 60 different genetic protein partners
(Rowley J, 1993; Daser A, 2004; Daser A, 2005). MLL translocations are known to
occur at a higher frequency in pediatric leukemias, arising before the age of one, and also
in therapy-related leukemias when compared to other leukemia subtypes (Huret J, 2001).
MLL-AF4 and MLL-AF9 fusions account for the majority of childhood leukemia cases,
whereas MLL-ENL accounts for the majority of MLL fusions occurring in therapyrelated leukemias (Huret J, 2001; Daser A, 2004; Daser, A 2005). A subset of therapyrelated leukemias arises in patients receiving topoisomerase II inhibitor treatment for a
primary cancer, later developing MLL leukemia (Daser A, 2004).
Since the prognosis for patients with MLL translocations is rather poor,
researchers are trying to find a cure for these leukemias, like in the case of BCR-ABL
(Rubnitz J, 1994; Rubnitz J, 1999). A treatment for BCR-ABL associated leukemia was
developed by studying the enzymatic function of the fusion protein and developing an
inhibitor towards the kinase activity of ABL (Buchdunger E, 1998; Druker B, 1996).
Treatment with imatinib, a small molecule inhibitor of BCR-ABL, leads to cancer
regression and a marked increase in 5 year cancer-free survival (Deininger M, 1997;
Druker B, 1996). Developing a small molecule inhibitor for the treatment of MLL fusion
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leukemias requires more ingenuity as the C-terminal fusion partners are variable, and the
N terminal portion of MLL-N which is retained in all MLL fusion protein does not have a
domain containing intrinsic enzymatic activity. The most common partners of MLL, are
AF4, AF9, and ENL, which do not have enzymatic activity, but are components of the
transcriptional elongation complex. Therefore traditional enzymatic inhibitors cannot
target multiple MLL fusions. New classes of inhibitors that block protein-protein
interactions have been used to disrupt interactions that are important for transformation.
Recent work uses inhibitors to target the Menin binding domain. Menin has been
previously shown to be required for MLL leukemogenesis, and disruption of Menin-MLL
interaction is believed to prevent transformation (Liedtke M, 2009; Grembecka, J 2010).
Since the non translocated allele of MLL is believed to be required for leukemic
transformation by the MLL fusion gene, experiments are on their way to target the SET
domain in the wild type protein to inhibit leukemia (Thiel A, 2010; Schapira M, 2011).
The MLL protein was found to be necessary for stem cell immortalization ex vivo
and for leukemogenesis in a mouse bone marrow transplantation assay (Thiel A, 2010).
MLL contains a SET domain which trimethylates histone H3K4 (Milne T, 2002; Milne
T, 2005a; Nakamura T, 2002). Dimethylation and trimethylation of the lysine 4 of
histone H3 (H3K4me2, H3K4me3) are marks of active transcription which are thought to
open chromatin and are permissive for gene transcription (Sims R, 2007; Bernstein B,
2002). Since the proposal of the histone code hypothesis (Strahl B, 2000; Jenuwein T,
2001) much work has been poured into understanding enzymatic proteins that put on
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(write), bind (read), and remove (erase) marks on histone tail residues (Strahl B, 2000;
Jenuwein T, 2001). A few of the ways in which histones can be modified are acetylation,
methylation, phosphorylation, ubiquitination, and sumoylation (Kouzarides T, 2007).
Another mechanism of chromatin modification is DNA methylation. Cytosine
methylation at CpG dinucleotides directly modifies DNA and the modification is
epigenetically inherited through the hemimethylase activity of the DNMT1 enzyme
(Jones P, 2001).
This study focuses on changes in histone 3 acetylation (ac) and methylation (me)
at MLL target genes. Acetylation of lysines on the histone tails is correlated with
transcriptional activation (Kurdistani S, 2004; Wang Z, 2008). Methylation marks on the
other hand have been associated with both transcriptional activation and repression of
gene activity depending on the residue modified. H3K4me3 is associated with
transcriptional activity, whereas trimethylation of H3K9 and/or H3K27 is correlated with
transcriptional gene repression (Kurdistani S, 2004). H3 lysine residues such as H3K14,
and H3K18, are acetylated, whereas H3K9 and H3K27 can be either acetylated or
methylated (Roth S, 1999; Grant P, 2001; Cao R, 2002; Rea S, 2000). Histone
acetyltransferases (HATs) or histone deacetylases (HDACs) function to write or erase
acetyl marks respectively (Lee K, 2007; Roth S, 2001). Histone methyltransferases
(HMTs) or histone demethylases (HDMs) function to write or erase methyl marks (Lee
M, 2006; Cloos P, 2008).
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Wild type MLL protein
MLL-N

Menin

Ledgf AT
hooks

PHD
CXXC 1-3

RD

MLL-C

BRD

AD

SET
domain

MLL-ENL fusion protein
Menin
Ledgf AT
hooks

MLL CXXC ENL
RD

AD

Figure 1. MLL is a large multi-domain protein that is translocated in a subset of
leukemias.
A) Shown are the Menin and Ledgf binding site, the AT-hooks, the RD
(repression domain), the PHD fingers, the bromodomain, and the FYRN and FYRC
domains, as well as the activation domain (AD) and the SET domain. The RD binds the
HDAC1, BMI1, hPC2, CtBP co-repressors, and the PAF1 component of an elongation
complex. The FYRN and FYRC domains are important for MLL-N interaction with
MLL-C after taspase cleavage. The AD binds CBP, a histone acetyltransferase, and
MOF, another HAT with specificity for H4K16, binds nearby (Dou Y, 2005). The
H3K4me3 mark is placed by the HMT activity of the SET domain of MLL. B) The MLL
fusion protein is shown. The breakpoint region in the MLL gene occurs 5' to the PHD1
encoding sequence (Akhtar A, 2000; Akhtar A, 2001).
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MLL is a multidomain protein that binds both co-activators and co-repressors.
MLL is post-translationally cleaved by the protease, taspase 1 (Hsieh J, 2003). Once the
full-length MLL protein is cleaved, the MLL-N and MLL-C fragments associate with one
another to form a functional MLL by way of the PHD1, PHD4, and FYRN domains of
MLL-N and the FYRC domain of MLL-C (Fig. 1) (Yokohama A, 2011). CYP33, a
protein that binds to MLL, seems to negative modulate expression of MLL target genes,
such as CDNK1B, MYC, HOXC8, and HOXA9 (Anderson M, 2002; Fair K, 2001; Park S,
2010). Over-expression of CYP33 promotes recruitment of the histone deacetylase
HDAC1 to the RD domain of MLL. CBP, a transcriptional co-activator that acetylates
H3, has been shown to bind to the activation domain of MLL-C, whereas HDAC1,
HDAC2, BMI1, hPC2, and CtBP have been shown to bind to the MLL-N repression
domain (Fig. 1) (Ernst P, 2001; Xia Z, 2003; this study).
The third plant homeodomain (PHD3) of MLL-N has been shown to bind
H3K4me3, a histone mark of active chromatin (Wang Z, 2010; Hom R, 2010; Park S,
2010). The enzymatic activity of the MLL SET domain on MLL-C writes the H3K4me3
mark on histone H3 (Milne T, 2002; Milne T, 2005a; Nakamura T, 2002). Therefore
MLL can both place and recognize the H3K4me3 mark through two independent
domains. The PHD3 is the reader and the SET domain is the writer. The PHD3 has been
shown to be important for leukemogenesis, as its loss from the MLL fusion proteins is
required for transformation ex vivo (Chen J, 2008; Muntean A, 2008). A possible
explanation is that wild type MLL is a regulated activator of transcription when binding
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to CYP33 switches MLL from an activator to a repressor. The fusion protein is a
constitutive activator of transcription: accordingly, it is necessary to lose the PHD3 finger
in the fusion protein for cellular transformation to occur.
CYP33 is a small protein that contains an RRM domain and a cyclophilin domain
separated by a conserved spacer (Fig 9). The CYP33 RRM (RNA recognition motif)
domain binds to the PHD3 (3rd PHD finger domain) of MLL. Repression of MLL target
genes not only requires the RRM of CYP33 to bind to MLL, but also requires the cistrans peptidyl-prolyl-isomerase (PPIase) activity of the CYP33 cyclophilin domain
(Anderson M, 2002; Fair K, 2001). PPIases participate in protein folding, signal
transduction, trafficking, assembly, and cell cycle regulation (Göthel S, 1999; Hunter T,
1998). Nelson et al. showed that Fpr4, a FKBP prolyl isomerase, regulates the cis-trans
conformation of the H3K37-H3P38 prolyl bond in the Histone H3 tail. The correct
conformation of this bond is necessary to allow for H3K36 methylation by SET2, and
efficient transcriptional elongation (Nelson C, 2006). This provides evidence that cistrans prolyl isomerases regulate gene transcription by targeting histone prolyl-peptide
bonds.
Although it has been known that HDAC1 is recruited to MLL in a CYP33dependent manner (Xia Z, 2003), the molecular mechanisms of this interaction at the
chromatin level have not been analyzed to this point. Also the specific role of CYP33s
PPIase activity is not well defined. In this study, through the use of coimmunoprecipitations (CoIPs) and chromatin immunoprecipitations (ChIPs), the question
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of whether CYP33 recruits HDAC1 and BMI1 to the chromatin in a CYP33-specific
PPIase-dependent manner was tested. Previously in our lab, Mark Koonce addressed the
question of HDAC1 recruitment dependence on PPIase activity. General PPIase activity
within the cell was inhibited by (Cyclosporin A). CsA is not specific to CYP33 but
inhibits other cyclophilins that are present in the cell, including Cyclophilin A. Koonce
showed that HDAC1 was not recruited to MLL by CYP33 when the PPIase activity of
CYP33 was inhibited by CsA (Koonce M, 2004).
Four separate enzymatic complexes compete to either put on or take off H3K27ac
or H3K27me3 histone marks: HATs, HDACs, HMTs, and HDMs (Fig. 2). The histone
methyltransferase that is responsible for trimethylation of H3K27 is Ezh2, a core
component of the PRC2 complex. HDAC1, the enzyme that is responsible for
deacetylation of H3K27, is part of both the MLL complex and the PRC2 complex (Xia, Z
2003, Van der Vlag, J 1999).
TrxG (Trithorax Group) and PcG (Polycomb Group) proteins function
antagonistically to one another (Ringrose L, 2004; Hanson R, 1999). In a simplified
view, TrxG proteins maintain genes in an active state, whereas PcG proteins function to
maintain genes in a repressed state. The significance of HDAC1 and its role in TrxG and
PcG-mediated gene repression has not been thoroughly explored, but it has been
suggested that HDAC1 is necessary to remove the H3K27ac mark to allow for PRC2
(Ezh2) to methylate H3K27 (Tie F, 2009; Pasini D, 2010). It is possible that HDACs
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HMTs
Ezh2
(PRC2)

H3K27me3

HDACs
HDAC1
CYP33

H3K27
HDMs
UTX
JDJM3

H3K27Ac
HATs
CBP
(MLL)

HDM-Histone Demethylase
HAT-Histone Acetyltransferase
HMT-Histone Methyltransferase
HDAC-Histone Deacetylase
Figure 2. Various enzymes function to acetylate, methylate, deacetylate or
demethylate H3K27.
Listed above are the enzymes involved in the addition or removal of acetylation
or methylation from H3K27. The enzymes modifying H3K27 are often found in large
complexes bound to specific promoters and their activity can be influenced by other
histone modifications (see text).
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have a similar function in the MLL complex to deacetylate the histone H3 tail, thereby
mediating MLL gene repression.
Several possible roles for H3K27ac have been proposed. It has been proposed by
groups studying both Drosophila and Mouse models that a possible role of H3K27ac is in
the inhibition of H3K27 trimethylation (Tie F, 2009; Jung H, 2010; Pasini D, 2010).
CBP over-expression in Drosophila was shown to prevent H3K27 trimethylation through
a Trx-dependent mechanism (Tie F, 2009). CBP is the HAT responsible for H3K18ac
and H3K27ac (Jin Q, 2011). Therefore, one of the purposes of this study was to
determine if MLL-associated histone acetylation fulfills the same function in mammalian
cells, and if CYP33 is part of the switch that shifts H3K27ac to H3K27me3. H3K27ac is
highly correlated with transcription and has been proposed to be a mark for active
enhancer elements in Drosophila and ES cells when paired with H3K4me1 (Wang Z,
2008; Creyghton M, 2011).
We propose that CYP33 functions to regulate MLL target gene transcription by
recruiting co-repressors HDAC1 and BMI1 to the MLL RD domain in a PPIasedependent manner. Conversely, we examined whether knockdown of CYP33 leads to a
decrease of HDAC1 and BMI1 at the promoters of MLL target genes. The recruitment of
HDAC1 to MLL RD at the chromatin was previously shown to lead to decrease of H3ac
levels at HOXA9 and HOXC8 gene promoters (Wang Z, 2010; Koonce M, 2004). It has
been shown that loss of H3K27ac leads to an increase in H3K27me3 in both Drosophila,
and mouse ES cell models (Pasini D, 2010; Tie F, 2009). The histone marks of H3 at
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MLL target genes were studied, focusing especially on the acetylation and methylation of
H3K27. CYP33 was over-expressed to determine if CYP33 decreased H3K27ac by
recruitment of HDAC1, which led to an increase of H3K27me3 deposited by the PRC2
complex. Recruitment of co-repressors HDAC1 and BMI1 bound to MLL targets gene
promoters CDNK1B, MYC and SIX1 was monitored after over-expression of CYP33.
The role of the PPIase was examined by using a PPIase mutant, called CYP33 M.
Finally, H3K27 acetylation and methylation were studied at MLL target genes to
determine if CYP33 affects histone acetylation or methylation levels. Through these
studies it was shown that H3K27ac is decreased or increased upon CYP33 overexpression or knockdown at MLL target gene promoters. This decrease of H3K27ac is
accompanied by HDAC1 and BMI1 increased recruitment to the repression domain of
MLL. Therefore, CYP33 functions to repress MLL target genes in part by decreasing
H3K27ac, a mark of active transcription.

CHAPTER II
REVIEW OF THE LITERATURE

CYP33 contains isomerase activity toward prolyl-peptide bonds in amino acid
peptide chains. Upon binding to MLL, CYP33 is thought to negatively regulate MLL
target genes in a PPIase dependent manner, thus switching MLL function from
transcriptional activation to a repression. It has been shown that either Cyclosporin A
(CsA), a non specific inhibitor of cis-trans prolyl isomerase activity, or Trichostatin A
(TsA), which inhibits the deacetylase activity of HDACs, counteracts the ability of overexpressed CYP33 to repress transcription of MLL target genes in 293T cells (Xia Z,
2003; Fair K, 2001; Anderson M, 2002). The repressive function of CYP33 is also
dependent upon the interaction between the RRM of CYP33 and the PHD3 of MLL
(Anderson M, 2002; Fair K, 2001; Park S, 2010; Wang Z, 2010; Hom R, 2010).
Although it has been shown that HDAC1 is recruited to MLL upon CYP33 overexpression, the molecular mechanisms by which CYP33 contributes to MLL-mediated
gene repression have not been thoroughly studied (Xia Z, 2003; Fair K, 2001). The
prevailing hypothesis is that CYP33 recruits HDAC1 to the chromatin which leads to a
higher concentration of HDAC1 at MLL target gene promoters, which in turn leads to a
decrease in H3 acetylation. Deacetylation of histone tails leads to compaction of the
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nucleosomes, closing of the chromatin and subsequent repression of gene transcription
(Shahbazian M, 2007).
MLL is a 430kD protein that contains multiple domains, many of which are
currently under study in order to determine their function. MLL is well known for the
critical role it plays in a subset of leukemias (Yu B, 1995; Hess J, 1997). Leukemia is a
cancer of the blood that was diagnosed in forty four thousand Americans in 2011; two
hundred seventy thousand Americans currently suffer from leukemia (Siegel R, 2012).
Proteins arising from mutant genes called oncogenes can cause abnormalities in a cell
leading to changes in cell proliferation, apoptosis, and/or other cellular processes that
lead to cancer. Cancer cells arise from normal cells when they acquire gain-of-function
mutations in proto-oncogenes and concomitantly lose the function of tumor suppressor
genes. Various processes occur in cancer progression including: 1) the ability to become
self-sufficient in the production of growth factors; 2) insensitivity to anti-growth signals;
3) evasion of apoptosis; 4) sustained angiogenesis; and 5) tissue invasiveness and
metastasis (Hanahan D, 2000). The Mixed Lineage Leukemia gene (MLL) is involved in
the initiation of leukemia when it becomes translocated and subsequently fused to partner
genes creating an oncogene which encodes a chimeric protein; over 60 separate MLL
partner genes in gene fusions have been documented (Daser A, 2004). MLL fusion
proteins lose the ability to bind CYP33 by virtue of the loss of the PHD3 finger. CYP33
is unable to repress the promoters of MLL target genes in the presence of such fusion
proteins (Chen J, 2010). Expression of MLL fusion proteins such as MLL-AF4, MLLAF9, or MLL-ENL leads to the increased expression of MLL target genes such as
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HOXC8, HOXA9, MYC, MEIS1 and CDNK1B (Wang Q, 2011; Xia Z, 2005; Ayton P,
2003; Ferrando A, 2003; Horton S, 2005). The over-expression of some of these genes,
specifically HOXA9 and MEIS1, play an important role in the leukemic phenotype
(Rozovskaia T, 2001; Faber J, 2008)
MLL domains linking structure and function
MLL is a 430kD protein that is proteolytically cleaved by taspase I to form a
MLL-N terminal 320kD protein (MLL-N), and an 180kD MLL-C terminal protein
(MLL-C) (Hsieh, J 2003). MLL-N and MLL-C after cleavage interact through their
FYRN and FYRC domains in order to maintain protein stability (Liu H, 2007; Yokohama
A, 2011). MLL contains many domains currently being studied for their role in gene
trans-activation. Starting from the N-terminus and working towards the C-terminus,
MLL contains menin, ledgf, binding domains, along with three AT hooks. Following the
AT hooks is the repression domain which contains the CXXC domain. Next are the PHD
fingers, and the atypical bromodomain followed by the PHD4 and the FYRN domain.
MLL-C contains the activation domain, which binds CBP, the FYRC domain and the
SET domain. MLL-N contains a menin binding domain. Menin functions to promote
oncogenesis in the hematopoietic lineage and to prevent oncogenesis in the endocrine
lineage (Yokoyama A, 2008; Yokoyama A, 2005; Wang E, 1998). Menin functions to
tether LEDGF to MLL, which is important for leukemogenesis by MLL fusions
(Yokoyama A, 2008; Roudaia L, 2008). C terminal to the Menin binding domain is a
series of AT hooks, a short motif consisting of an arginine-glycine-arginine-proline
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tetrapeptide repeat (Aravind L, 1998; Reeves R, 1990). AT hooks are found in HMG1
proteins and help to anchor proteins to DNA (Aravind L, 1998). Multiple interactions
contribute to MLL binding to its target genes. AT hooks and LEDGF binding, along with
the CXXC domain (located within the repression domain) contribute to MLL binding to
target genes (Cierpicki T, 2010; Erfurth F, 2008). Comprehensive, genome-wide studies
have not been conducted on deletions of MLL domains and binding to target gene
promoters. MLL target genes are discussed in a subsequent section.
C-terminal to the AT hooks, there is a conserved region called the repression
domain (RD). The RD is the minimal region needed for repression of MLL target genes,
as shown in a CAT reporter assay (Zeleznik-Le N, 1994). The RD domain contains the
canonical CXXC motif which binds unmethylated CpGs in the DNA major groove (Birke
M, 2002; Cierpicki T, 2010). Deletion of CXXC or disruption of its ability to bind
unmethylated CpGs in the context of MLL fusion proteins leads to their decreased ability
to transform cells (Cierpicki T, 2010; Bach C, 2009). The RD has been shown by coimmunoprecipitation (CoIP) and GST immunoprecipitation assays to bind to the proteins
HDAC1, hPC2, BMI1, and CtBP (Xia Z, 2003). In the same report, it was shown that
CYP33 increases the recruitment of HDAC1 to the MLL RD. Dependence on CYP33 for
the binding of other repressive proteins to the MLL RD, such as HPC2, BMI1, and CtBP,
was not tested (Xia Z, 2003). HDAC1 is an enzyme that functions to deacetylate both
histone and non-histone substrates. Increased recruitment of HDACs to MLL target
genes may have several consequences. HDAC1 can deacetylate the histone tail of H3,
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leading to chromatin compaction (Shahbazian M, 2007). Also, HDACs such as SIRT2
and HDAC1 can deacetylate CBP, leading to a decrease in the ability of CBP (p300) to
transactivate target genes (Stiehl D, 2007; Black J, 2008). CBP and MOF, two HAT
proteins can independently bind to the activation domain of MLL and regulate histone
acetylation (Dou Y, 2005; Ernst P, 2001). Although the roles of HDAC1, HPC2, BMI1,
and CtBP have been studied in other complexes, the specific roles of these proteins in the
MLL gene repressive mechanism are still poorly understood. Besides co-repressors, the
RD binds PAF1, a component of the PAF elongation complex, and has been shown to be
important for MLL recruitment and transactivation (Muntean A, 2010; Milne T, 2010).
The PAF complex associates with RNA Pol II and functions to recruit histone
modification enzymes (Crisucci E, 2011).
C terminal to the MLL RD lays a cluster of three PHDs. This PHD cluster is
closely followed by a bromodomain and a fourth PHD (PHD4) (Fig 1). Loss of the
PHD3 finger in MLL is necessary for MLL-ENL or MLL-AF9 cellular transformation
(Chen J, 2008; Muntean A, 2008). The MLL fusion protein cannot transform bone
marrow cells when the PHD cluster or the PHD3 alone are re-inserted into the MLL
fusion protein (Chen J, 2008; Muntean A, 2008). Therefore MLL fusion proteins
containing the PHD3 are not found in leukemia patients, nor cause leukemia in mouse
models. Upon reintroduction of PHD3 or the PHD finger cluster into the MLL fusions
MLL-ENL or MLL-AF9, CYP33 is able to bind to the fusion proteins and repress
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HOXA9 expression, and the modified fusion proteins lose their ability to mediate bone
marrow transformation in serial colony-plating assays (Chen J, 2008; Muntean A, 2008).
The PHD fingers have been shown to be versatile readers of different histone tail
modifications (Sanchez R, 2011). MLL, like other PHD bearing proteins such as BTPF
and ING2, binds specifically to H3K4me3 (Pena P, 2006; Wysocka J, 2006; Wang Z,
2010; Hom R, 2010; Park S, 2010). This is a histone modification mediated by the
methyltransferase enzymatic activity of MLL which resides in its SET domain (Table 1).
Hence it has been suggested that MLL is important for propagation of the H3K4me3
mark, as it can both read (bind to) and write (place) the H3K4me3 mark. Besides binding
to H3K4me3, the MLL PHD3 also binds the RRM domain of CYP33. The binding of
CYP33 to MLL reduces the affinity of the PHD3 for H3K4me3 (Wang Z, 2010; Park S,
2010). H3K4 trimethylation upon CYP33 over-expression is reduced at MLL target
genes (Park S, 2010)
Bromodomains typically have been shown to bind acetylated (ac) lysine residues.
MLL1 contains an atypical bromodomain, which is located between PHD3 and PHD4.
In vitro experiments show that the bromodomain of MLL does not bind to ac-lysine
residues (Wang Z, 2010). Instead it has been hypothesized by Wang et al. that the MLL
bromodomain may function to inhibit the recruitment of CYP33 to MLL by steric
hindrance of the CYP33 binding surface on PHD3. An extra regulatory step is
isomerization of the H1628-P1629 prolyl bond which is located between the PHD3 and
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Table 1: PRC1/PRC2 complex components
Polycomb Repressive Complex 2
Core Components
Rbp48
EED
SUZ12
EZH1/EZH2
Polycomb Repressive Complex 1
Core Components
Pc1/Pc2 (CBX/CBX4)
BMI1
Ring1a/Ring1b
PH

General Function in the complex
Binding of complex to the chromatin
Binding to H3K27me3
Essential for histone methyltransferase activity of
PRC2
Contains SET domain necessary for H3K27
methylation

Binds to H3K27me3
Required for ubiquitination by Ring1a/1b
Ubiquiylates H2AK119

Modified from Review by Morey and Helin (Trends in Biochemical Sciences (2010).
323-332.)
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bromodomain and is necessary to uncover the CYP33 binding surface on the PHD3
finger. This isomerization may be catalyzed by the cyclophilin domain of CYP33 (Wang
Z, 2010).
Named after three proteins in which it was found, Suvar39, Enhancer of Zeste,
and Trithorax, the SET domain of MLL1 is responsible for methylating H3K4 at a subset
of genes within the cell (Wang P, 2009). Six HMT complexes have been found to date
that can methylate H3K4. SET domain-containing proteins that methylate H3K4 include
SET1A, SET1B, MLL1, MLL2, MLL3, and MLL4 (Wang P, 2009; Kouzarides T, 2007;
Slany R, 2009). During development and differentiation, the enzymatic activity of the
SET domain is a key function of MLL, as shown in knock-in mice expressing a truncated
MLL lacking the SET domain. MLL mice expressing a truncated form of MLL do
survive embryonic life, but they display a strong mutant phenotype, consisting of skeletal
defects, and altered HOX gene transcription (Terranova R, 2006). As shown in Table 1,
H3K4me3 is a mark of activation found on nucleosomes at the promoters of actively
transcribed genes (Wang P, 2009). MLL, which is part of the Trithorax group (TrxG) of
proteins, is in part responsible for maintaining a subset of genes in an active state. It does
this by a variety of mechanisms. First, it can methylate H3K4me3, which is a mark
associated with gene activity (Guenther M, 2007). Second, it can associate with
components of the SWI/SNF chromatin remodeling complex (Rozenblatt-Rosen O,
1998). Third, it can associate with transcriptional co-activators such as CBP which lead
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to acetylation of histones (Ernst P, 2001). The SET enzymatic activity has been shown to
be increased in the presence of H3ac peptides (Milne T, 2002; Nakamura T, 2002).
In contrast to the TrxG family of proteins, Polycomb Group (PcG) proteins
function in gene silencing. These proteins place repressive marks such as the H3K27me3
mark and H2AK119 ubiquitination, thus maintaining genes in a silent state (Fig. 2). Two
well-studied PcG complexes are PRC1 and PRC2, and a further analysis of these
complexes will be addressed in a subsequent section.
The role of prolyl isomerases (PPIase) in cellular function
There are three families of cis-trans prolyl isomerase proteins: cyclophilins,
FK506-binding proteins, and parvulins (Handschumacher R, 1984; Harding M, 1989;
Wang P, 2005). CYP33, falls into the cyclophilin protein family. Each of these families
has a different structure and enzymatic active site. The structure of the cyclophilin
domain-containing family of proteins consists of an eight-stranded β-barrel covered by
two α-helices, with a hydrophobic pocket that can bind CsA (Cyclosporin A) (Ke H,
1993; Mikol V, 1993; Gamble T, 1996; Wang T, 2005). CsA is a natural inhibitor of the
PPIase activity of cyclophilins (Takahaski N, 1989; Handschumacher R, 1984; Wang P,
2005). Cyclophilins are conserved from bacteria to humans, and the CYP33 protein is
highly conserved from Caenorhabiditis elegans to Homo sapiens (Anderson M, 2002;
Wang P, 2005). MLL and CYP33 interact in Drosophila, mouse, and Homo sapiens.
The prolyl peptide bond N terminal to the proline can adopt a cis configuration
within proteins at a relatively high probability (Brandts J, 1975; Grathwohl C, 1976;
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Levitt M, 1981). This is due to the intrinsic structure of the proline residue. Other amino
acid residues have a much lower probability to be found in the cis conformation (10-3
versus 0.1-0.3 for proline) (Ramachandran G, 1976). Although a prolyl peptide bond has
a higher probability to be found in either the cis or trans position within proteins, the
spontaneous reaction in the absence of an enzyme is slow to reach equilibrium (Schmid
F, 1993). This may lead to an additional step in the regulation of proteins with critical
residues that need the peptidyl prolyl bond to be either cis or trans before a complex can
form or a covalent modification can be added.
It has been shown that cyclophilins are involved in a variety of important cellular
processes including: pre-mRNA splicing protein and lipid trafficking, protein complex
assembly and disassembly, signal transduction, protein folding, and the regulation of
gene transcription (Horowitz D, 2002; Price E, 1994; Hunter T, 1998; Anderson L, 2011;
Fischer G, 1990; Nelson C, 2006; Shaw P, 2007).
Cyp33, its PPIase function, and RRM domain
CYP33 is a cis-trans prolyl isomerase which is 33 kD in size. It is a protein
containing both an RRM (RNA Recognition Motif) domain and a cyclophilin domain
separated by a spacer region part of which is highly conserved in amino acid sequence
throughout evolution (Mi H, 1996). CYP33 belongs to the cyclophilin class of PPIases
(see above). CYP33 was originally found in T-cells as a novel cyclophilin that binds
RNAs (Mi H, 1996). Its cyclophilin domain is structurally similar to Cyclophilin A and
binds CsA (Wang T, 2005). The RRM domain folds into five anti-parallel β-sheets and
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two α-helices, as determined by x-ray crystallography (Hom R, 2010; Park S, 2010;
Wang Z, 2010). It was found that CYP33 binds to poly-A and poly-U RNA sequences in
vitro (Mi H, 1996; Solanki J, unpublished). CYP33 has been shown to bind to the
mRNA sequence AAUAAA, which is the poly-A addition signal (Wang Y, 2008).
Binding to the poly-A addition signal was shown to stimulate CYP33’s PPIase activity,
although no in vivo data was shown, and the significance of the small increase in PPIase
activity by binding to mRNA was not addressed (Wang Y, 2008).
CYP33 was revealed to bind to the PHD3 finger of MLL during a yeast twohybrid study where the PHD3 of MLL was the bait. Binding was further confirmed by
CoIP experiments, GST immunoprecipitations, and imaging co-localization studies (Fair
K, 2001; Anderson M, 2002). In addition to the discovery that CYP33 binds MLL, these
reports also showed a functional relationship between CYP33 protein levels and MLL
target gene transcript levels as the over-expression of CYP33 leads to the downregulation of MLL target genes. This repression was dependent upon the PPIase activity
of CYP33. The evidence revealed that after the addition of CsA, over-expression of
CYP33 was no longer able to repress HOXC8, an MLL target gene (Fair, K 2001,
Anderson, M 2002). Over-expression of a truncation mutant of CYP33 that lacks the
PPIase domain (CYP33Δ) did not result in repression of HOXC8 gene expression as well
In a subsequent study, HDAC1 was shown to be recruited to MLL by CYP33, and both
CsA and Trichostatin A (TSA), an HDAC inhibitor, could inhibit the target gene

23
repressive activity of CYP33 (Xia Z, 2003). In the presence of TSA or CsA, CYP33 no
longer represses HOXC8, an MLL target gene, in 293T cells.
The RRM domain of CYP33 binds specifically to the MLL PHD3, but does not
bind to other MLL PHD (Fair K, 2001; Hom R, 2010). Interaction of the PHD finger and
the RRM domain disrupts RNA binding to RRM; CYP33 has a higher affinity for PHD3
than for RNA, according to in vitro data (Hom R, 2010). Results from our lab show that
specific RNA sequences can disrupt the binding of PHD3 and CYP33 (Solanki J, 2011).
The PHD3 binds to H3K4me3 or CYP33 in a mutually exclusive manner (Wang Z, 2010;
Park S, 2010). Thus the hypothesis was proposed that when CYP33 is present, the PHD3
is unable to bind H3K4me3 and propagate the mark. Both of these studies relied heavily
upon in vitro methods, conducting very few experiments ex vivo (in tissue culture). Most
of the evidence provided in favor of the hypothesis relied on NMR and X-ray
crystallography. I emphasize this to suggest that more work needs to be conducted in
order to understand the complex nature and function of the RNA-CYP33 and MLLH3K4me3 interactions.
The targets of the CYP33 PPIase activity have not been fully explored. There are
two studies that look into this. A study by Wang et al. shows that CYP33 isomerizes the
prolyl bond H1828-P1629 of MLL between the PHD3 and the bromodomain (Wang, Z
2010). They hypothesize that the z-α helix of the bromodomain blocks CYP33 binding to
the PHD3 finger, and a conformation shift has to take place before CYP33 binding can
occur. The identification of the prolyl bond H1628-P1629 as a substrate does not exclude
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the possibility that CYP33 could have other cellular substrates, on MLL, HDAC1,
histone H3 or other proteins. Histone H3 is an attractive candidate as it has been
previously show to be a target of Fpr4, a FKBP PPIase in yeast (Nelson C, 2006). Since
the MLL/CYP33 interaction seems to have complex functions at the chromatin level, it is
reasonable to hypothesize that CYP33 could target prolyl bonds on the histone H3 tail.
Using an in vitro chymotrypsin-coupled assay, using a histone H3 peptide substrate, this
was shown to be the case. H3 is isomerized by CYP33 at H3P16 and H3P30 (Fig. 3)
(Park S, 2010). The H3 A29-P30 prolyl bond is interesting for this study as H3K27 is
only two amino acid residues away, and it is conceivable that the cis-trans state of this
bond is important for acetylation or deacetylation of this residue. The spontaneous
reaction of cis to trans in the absence of PPIase activity is slow (Nagradova N, 2010). A
reasonable hypothesis is that CYP33 isomerizes H3 in order to allow deacetylation of
H3K27 by HDAC1. HAT and HDAC1 have been tested for activity in the presence of
CypA for the G13-P14 prolyl bond (Schultz, R. unpublished). In an in vitro assay it was
shown that the activity of HDAC1 but not HAT increases towards lysine 14 in a peptide
substrate in the presence of CypA.
Therefore the hypothesis that needs to be tested is whether CYP33 leads to a
decrease in H3K27ac and allows for H3K27me3 (subject of this study). CYP33 could
lead to a decreased H3K27ac in a couple of ways. One, CYP33 increases HDAC1
recruitment to MLL. The increased HDAC1 would lead to a reduction of H3K27ac at the
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B)

Figure 3. Histone tails such as H3 can be isomerized by the PPIase activity of
cyclophilin domain containing proteins such as CYP33
A) Schematic of the histone tail showing lysine and proline residues in the N
terminus of H3. B) A chymotrypsin-coupled reaction as shown above using a partial
substrate of H3 shows how the CYP33 PPIase activity was assessed by Peter Breslin and
Sango Park (Breslin, P unpublished; Park S, 2010).
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promoters of MLL target genes. Two, CYP33 could isomerize H3P30 and allow for a
better substrate for HDAC1, thereby decreasing H3K27ac.
MLL target genes
A well-studied group of MLL target genes are the HOX genes, a group of genes
involved in body patterning during development. The HOX genes are organized in four
gene clusters in mice and humans. MLL1 has been shown to regulate the more 5' genes
of the HOX gene clusters. Well studied for their role in hematopoiesis HOX genes are
not expressed within MSA cells (Lawrence, H 1996). MSA cells are a thyroid carcinoma
cell line which will be used to study the role of repression of MLL target gene expression
by CYP33. MSA cells were found to have low levels of HOX genes HOXC8 and HOXA9
and were believed to be an ideal cell line to study the role of CYP33 knockdown upon
MLL mediated gene transcription.
Another theme that is emerging within the field of TrxG and PcG proteins about
targeting to specific target genes within a cell is the role of non-coding RNA (ncRNA).
MLL and PcG proteins have been shown to bind ncRNA. This is believed to help target
TrxG and PcG proteins to specific target gene promoters, and to help maintain genes in
the active (On) or repressive (Off) state (Papp B, 2006). Accordingly, there is a critical
role for ncRNA in MLL-mediated maintenance of gene expression. One example is
Mistral, which is a non-coding RNA that can target MLL to HOXA6 and HOXA7 in stem
cell differentiation (Bertani S, 2011). In addition, ncRNAs have been linked to
recruitment of PRC2 proteins to specific loci (Gupta R, 2010; Kotake, 2011). Therefore,
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non-coding RNAs control chromatin architecture in trans and may play an important role
in regulation of gene activity (Mattick J, 2001).
CYP33 also has been shown to bind to ncRNA specifically within RNA that is
transcribed between coding genes HOXC6 and HOXC8 (Solanki J, 2011). The function
of CYP33 binding to RNA is still under active investigation. Investigators Hom et al.
showed that RNA binds to CYP33 with a Kd of 198μM, and PHD3 with a Kd of 1.9μM
(Hom R, 2010). They hypothesize that CYP33 binds to MLL instead of RNA because
the interaction of CYP33 and MLL PHD3 have a higher affinity than CYP33 has for
RNA. Although Hom et al showed a high affinity bond between CYP33 and MLL, poly
A or RNAs with the consensus sequence containing YAAUNY were shown to be capable
of disrupting the CYP33/PHD3 finger interaction (Solanki J, 2011).
There are three studies (Wang Q, 2011; Wang P, 2009; Milne T, 2005) that
explore in detail the binding of MLL and MLL fusions proteins to chromatin. These
studies take a comprehensive look at MLL binding to the chromatin and try to gain a
better understanding of the role played by MLL and its targets in gene expression. They
vary in their conclusions about MLL target genes and their criteria for what qualifies as
an MLL target gene. One paper concluded that there may be as few as 500 such target
genes (Wang P, 2009), while another concluded that there may be as many as 5000
(Milne T, 2005a). Findings are based on high throughput methods such as ChIP analysis
followed by sequencing (ChIP-seq).

28
Four MLL target genes that were examined in this study are CDNK1B, MYC, and
SIX1. These have been shown to be regulated by MLL (Wang Q, 2011; Wang P, 2009;
Milne T, 2005). HOXC8 and HOXA9 are not expressed in MSA cells and thus were not
studied in this cell line, but they were examined in Mouse Embryonic Fibroblasts
(MEFs). P27 which arises from the CDNK1B locus plays an important role in cell cycle
regulation and is regulated by both MLL and MLL-fusion proteins (Xia Z, 2005). MYC,
a basic helix-loop-helix transcription factor, has been shown to be a MLL target gene
(Wang Q, 2011). The regulation of c-Myc is extremely complex, at both the levels of
transcription and translation. It plays a major role in cell proliferation and also in
hematopoietic cell differentiation and development. Additionally, it has been shown to
be important in embryonic cell development, as it is one of the four genes that can induce
pluripotent stem cells (Takahashi K, 2007). SIX1 is a homeobox domain protein. It is a
transcription factor having a role in neuronal differentiation and development; it has also
been shown to be amplified in breast cancer (Reichenberger K, 2005).
MLL fusions
Much work has been conducted attempting to provide mechanistic insights into
the pathogenesis of MLL leukemia, as they have particularly poorer prognoses than many
other forms of this disease (Ayton P, 2001). This provides motivation in the field to
develop targeted therapies for MLL leukemias. Currently, very little exists in the way of
MLL directed therapy. MLL leukemias represent a small proportion of total leukemias
which develop during infancy, under 1 year of age, and treatment-related leukemias.
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Some patients who present with primary solid tumors, such as breast and lymphoma, are
treated with topoisomerase II inhibitors. After treatment they are cured from their
original cancer only to discover later that they have developed MLL leukemia (Huret J,
2001; Bhatia S, 2002).
Recent evidence supports the hypothesis from Thiel et al. proposing that WT
MLL is necessary for the development of MLL fusion-mediated leukemia, as knocking
down or knocking out of WT MLL leads to loss of transformation and leukemogenicity
in mouse bone marrow cells (Thiel A, 2010). In addition, WT MLL is necessary for
HOX gene expression regulation by MLL fusions (Thiel A, 2010). It is hypothesized that
WT MLL is required to place the H3K4me3 mark and to maintain chromatin in an open
conformation, since the MLL fusion lacks a SET domain (see below). More research
aimed at understanding the role of WT MLL in MLL leukemia needs to be conducted.
Also a report by Milne et al. (Milne T, 2010) showed that WT MLL1 is needed for the
recruitment of the MLL fusion protein to the HOXA9 locus, and over-expression of
HOXA9 is necessary for transformation (Ayton P, 2003). In addition to its role in
leukemogenesis, MLL has an important role in both embryonic development and the
development of various tissues in the adult organism (Yu H, 1995). MLL has been found
to be involved in hematopoietic and neurogenic differentiation (Ernst P, 2002; Lim D,
2009).
The protein stability of WT MLL and MLL fusions has been shown to differ. WT
MLL protein is degraded during G1 and S phases of the cell cycle whereas the MLL
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fusion protein remains stable throughout the cell cycle (Liu H, 2007). Forced overexpression of MLL increases H3K4me3 levels at MLL target genes during S phase,
triggering recruitment of CDC45 and resulting in cell cycle arrest (Liu H, 2010). In
comparison to MLL, MLL fusion proteins lose the degradation signal located on the N
terminal portion of MLL; thus they are expressed at a constant level throughout the cell
cycle (Liu H, 2007).
Chromatin, MLL complex, and histone tail modifications
Chromatin is comprised of nucleosomes around which 147 nucleotides of DNA
are wrapped (Lugar K, 1997). A crystal structure of 2.8Å resolution revealed that
nucleosome complexes are composed of DNA and octamer of four histone proteins, H3,
H4, H2A, and H2B (Luger K, 1997). While histones were discovered at the turn of the
20th century, it was not until Jenuwein and Allis proposed the idea of the histone code
hypothesis that the study of the histone role in gene regulation was truly brought to the
forefront (Jenuwein, T 2001, Strahl B, 2000). The histone code hypothesis has had a
profound effect on how transcriptional regulation is viewed. The histone code hypothesis
states that the tails of histone proteins can be modified by the activities of various
proteins and that the "marks" added or subtracted by these histone-modifying proteins
lead to changes in the state of the chromatin. Histone tail modifications can act alone or
in combination to modulate gene transcription (Strahl B, 2000; Jenuwein T, 2001).
The MLL complex has the ability to place the H3K4me3 mark at the promoter of
MLL target genes. This is a mark of active transcription. H3K4me3 facilitates active
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transcription through a variety of mechanisms (Deaton A, 2011). It has been shown to
recruit NuRF chromatin remodeling complexes, to interact with the ING4 HAT complex,
and also to directly recruit the core transcriptional machinery via interaction with TFIID
(Li H, 2006; Ruthenburg A, 2007; Wysocka J, 2006; Saksouk N, 2009; van Ingen H,
2008; Vermeulen M, 2007).
Besides deposition of the H3K4me3 mark, MLL and trithorax (Drosophila
homolog) also recruit CBP (Creb binding protein) (Ernst P, 2001; Tie F, 2009; Petruk, S
2001). Accordingly, the MLL complex can deposit H3K4me3 and H3ac in order to
activate gene transcription. H3 acetylation has long been proposed to associate with
active chromatin (Allfrey V, 1964; Pogo B, 1966). This idea was proposed in 1964, and
in 1978 evidence showed that histone acetylation was associated with actively transcribed
chromatin (Vidali G, 1978; Hebbes T, 1988; Sealy L, 1978). In 2008, genome-wide
ChIP studies correlated 17 individual histone methylation and acetylation marks to active
or highly active chromatin, thus underscoring the chromatin complexity within actively
transcribed genes (Wang Z, 2008). H3K27ac and H3K4me3 were found in this study to
be associated with highly active transcription (Wang Z, 2008). H3K27ac is located
within the promoters of actively transcribed genes. Table 1 shows a brief list of the
complexes that play a role in H3K27.
Histone demethylases
Earlier it had been hypothesized that the methyl mark could only be removed
from the histone tail via proteolysis or dilution through histone replacement (Shi Y, 2004;
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Goll M, 2002). However, it is now known that histone demethylases play a pivotal role
in the regulation of histone methylation marks and that these enzymes play an important
role in diseases such as cancer. UTX and JMJD3 lead to the removal of H3K27me3,
whereas Jarid1A, Jarid1B, Jarid1C, and Jarid1D lead to removal of H3K4me3 (Klose J,
2006; Hong S, 2007; Swigut T, 2007). Demethylases, unlike HDACs, are generally
specific for a particular histone residue. An exception is LSD1 which demethylates
H3K4me2, H3K4me1, and H3K9me2,H3K8me1 (Shi Y, 2004; Shi Y, 2005). Recently,
it was shown that UTX and BRM, components of the SWI/SNF chromatin remodeling
complex, are necessary for demethylation and acetylation of H3K27ac in Drosophila (Tie
F, 2012). Many proteins are still being characterized for their role in demethylation of
histone tails. UTX has been shown to interact with MLL1 and MLL2 for demethylation
of H3K27me3, leading to an increase in gene transcription (Lee M, 2007).
In addition to lysine, arginine residues have also been shown to be methylated. A
separate class of enzymes, called PRMTs (protein arginine methyltransferases), write the
arginine marks on these residues on histone tails (Di Lorenzo A, 2010). Arginine can be
symmetrically or asymmetrically methylated and these lead to different transcriptional
outcomes. Symmetrically methylated H3R4me2 leads to an increase in recruitment to the
chromatin of WDR5, a coactivator of MLL, SET1A, SET1B, NLS1, and ATAC, whereas
asymmetrically methylated H3R4me2 leads to gene repression (Migliori V, 2012).
Deimination and conversion to citrulline by PADI4 inhibits methylation of arginine by
CARM1. (Cuthbert G, 2004; Wang Y, 2004).
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Transcriptional regulation
The accessibility of the chromatin due in part to maintaining various histone
marks is an important factor related to transcriptional initiation and elongation. Of equal
importance are the multimeric protein complexes, including the transcriptional cofactors
that function to regulate gene transcription. The role of MLL in marking gene loci with
the active mark H3K4me3 is well established (Ruthenburg A, 2007; Guenther M, 2008;
Chang P, 2010). The H3K4me3 mark is recognized by CHD1. It is hypothesized that
CHD1 facilitates pre-mRNA maturation by bridging spliceosomal components to
H3K4me3 (Sims R, 2007). The MLL fusion partners AF4 and AF9 are components of a
transcriptional elongation complex (Yokoyama A, 2010; Slany R, 2009). Therefore MLL
fusions may increase transcription of MLL targets by increasing transcriptional
elongation (Mueller D, 2009). CYP33 may also regulate transcription through MLLindependent mechanisms, as it has been shown to associate with XAB2 and the
spliceosome (Kuraoka I, 2008; Jurica M, 2003). Transcriptional regulation is only one
step in the process between transcriptional initiation and protein production.
During development transcription of MLL target genes, such as HOXC8, is
initiated through MLL-independent mechanisms (Yu H, 1998). After initiation of HOX
gene transcription in the early embryo MLL is critical to maintain HOX gene
transcription in subsequent development, and prevent genes from becoming silenced in
the developing embryo (Yu, B 1995). In the absence of MLL, HOX genes are turned off
during development (Yu H, 1998).
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Oscillations within cells, negative/positive feedback loops
Oscillations of gene transcription can be found in cells naturally through a variety
of different mechanisms. Cell cycle genes oscillate throughout the cell cycle in rhythms
that last around 24 hours in mammalian cells. By perturbing genes associated with
circadian rhythms, such as BMAL1 or CLOCK, these rhythms can be altered. CLOCK is
a histone acetyltransferase, and it has been shown that the activity of CLOCK is
important for circadian rhythm function (Doi M, 2006). MLL1 has been found in a
complex with CLOCK and BMAL1 and is important for circadian gene transcription and
methylation of H3K4me3 at circadian-transcribed genes (Katada S, 2010). Many cancer
cells have disrupted circadian rhythms (Sahar S, 2009). The pathways of the cell cycle
and circadian rhythms are not independent, but are linked through the DNA damage
protein XPA, and cell cycle regulators, MYC, p21, and Wee1 (Sancar A, 2010).
Circadian rhythms are controlled by a series of negative feedback loops (Ko C,
2006). These feedback loops are regulated by light/dark stimuli. Circadian rhythms
oscillate in synchronous cells in yeast (Klevecz R, 2004). Normal circadian feedback
loops can be simple: Gene A is expressed and its protein product negatively regulates its
own expression with delays in several steps of transcription, translation and protein
transport to the nucleus. Feedback loops also can be complex and have multiple gene
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Positive Feedback Loop

PA

PA
PA
PA gene
Negative Feedback Loop
PB

PB

PB
PB gene

PB gene

Figure 4. Representation of simple positive and negative feedback loops.
An example of a positive feedback loop is PA gene encoding the PA protein
which binds its promoter and stimulates its transcription. An example of a negative
feedback loop is the PA gene encoding the PA protein, a repressor which binds to its
promoter and decreases its transcription. A negative or positive feedback loop can
operate through a single gene, or through multiple genes and proteins and pathways.
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regulatory networks. Gene A regulates Gene B and Gene C, which then negatively
regulates Gene A. Figure 3 shows examples of positive and negative feedback loops.
MLL and the cell cycle, senescence, and MLL protein stability
Lastly, when studying MLL it is worth noting that it is cleaved into N- and Cterminal fragments by a protease, taspase1 (Hsieh J, 2003). This taspase-mediated
cleavage is conserved in evolution as the Drosophila Trx (MLL homolog), is also cleaved
by a taspase homolog (Capotosti F, 2007). The FYRN and FYRC domains along with
PHD fingers 1 and 4 are responsible for proper interaction of MLL-N and MLL-C (Hsieh
J, 2003; Yokohama A, 2011). MLL-N when overexpressed in cells by itself, apart from
MLL-C, is unstable (Liu H, 2007; Yokohama A, 2011). The stability of MLL-N and
MLL C-proteins is regulated through separate degradation mechanisms (Yokohama A,
2011).
In the cell cycle, MLL is regulated by protein degradation. During the S and G1
phases of the cell cycle, MLL is degraded by SCF and APC respectively, causing a
reduction in MLL target gene transcription (Liu H, 2007). MLL has also been shown to
be important for gene transcription after mitosis. In the absence of MLL, a large number
of genes that are silenced during mitosis suffer a delay in their reactivation during G1
(Blobel G, 2009). Consequently, MLL plays a broader role in the regulation of the cell
cycle than previously thought.
Senescence is a process by which a cell irreversibly exits the cell cycle (Kuilman
T, 2010). A couple of studies show that inhibition of cyclophilins, through CsA, lead to
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senescence. CsA treatment induces senescence in renal tubule epithelial cells through
induction of p21 and p16, and differentiation in K562 cells (Sawafuji K, 2003; Jennings
P, 2007). P27 has also been linked to Rb mediated senescence (Alexander K, 2001). It
was also found that knocking down MLL leads to a p53-dependent cellular senescence
response through upregulation of p21 in human derived fibroblasts (Caslini C, 2009).
PRC2 complex
The PRC2 complex consists of three core proteins along with many accessory
proteins: EED, Suz12, and Ezh2 (Cao R, 2004; Kuzmichev A, 2002; Montgomery N,
2005). A fourth protein, PHF1, has been shown to be necessary for efficient H3K27
trimethylation (Cao R, 2008; Sarma K, 2008). HDAC1 is also part of the PRC2 complex,
yet its role is not well understood (Table 2). The homolog of HDAC1, RPD3 has been
found to be a part of the drosophila PRC2 complex (Tie F, 2001; Tie F, 2003). HDAC1
has also been shown to be necessary for EED repression (van der Vlag J, 1999). Several
reports have shown that Ezh2 is over-expressed or deregulated in aggressive breast and
complex are over-expressed or lead to tumorgenesis in a variety of cancers including
breast, prostate, bladder, colon, lung, pancreatic cancer, sarcoma and lymphomas (Chang
C, 2012; Kleer C, 2003; Wilson B, 2010). Also beside Ezh2 being an oncogene, it has
also been shown to have a role as a tumor suppressor. Ezh2 and Suz12 were shown to be
decreased in a variety of T-ALLs (Ntziachristos P, 2012; Zhang J, 2012). Ezh1 is a
closely related homolog of Ezh2 in mammals. Ezh1 has methyltransferase activity for
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Table 2. A list of selected histone marks that are written or removed by TrxG and
PcG proteins and the complex that places or removes the marks.
Histone Mark

Known Function

H3K4me3

Transcriptional
initiation at the gene
promoter
Gene transcription,
allows for open
chromatin
High rate of
transcription
Heterochromatin
Gene repression
Gene repression may
be through chromatin
compaction

H3K9ac/
H3K14ac
H3K27ac
H3K9me3
H3K27me3
H2AK119ub

Complex/Enzyme
that places the mark
MLL complex/SET
domain of MLL

Complex/Enzyme
that removes mark
Jarid1A-D Complex

GCN5

HDACs

CBP

HDACs

SUV39H1
PRC2 complex/Ezh2
PRC1 complex
/RING1A/B

JMJD1A, JMJD2C
UTX, JMJD3
DUBs

Red-Marks that lead to the repression of gene transcription
Green-Marks that lead to the activation of gene transcription
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H3K27me3, and upon knockout or knockdown in ES cells, Ezh1 can partially
compensate for Ezh2 (Shen X, 2008). Ezh1 was also shown to be able to compensate for
Ezh2 in adult hematopoesis but it is unable to compensate for it in the fetal liver where it
is expressed at a lower level. Therefore Ezh2 is indispensable for the fetal liver
hematopoesis but it can be knocked down with little effect in adult hematopoesis in mice
(Mochizuki-Kashio M, 2011).
The prevailing hypothesis in the literature is that H3K27me3 is deposited upon
the chromatin by Ezh2 within the context of the PRC2 complex. Once the H3K27 mark
is deposited, hPC2, a component of the PRC1 complex, can then bind to the H3K27me3
with its chromodomain (Fischle W, 2003). This leads to repression of gene transcription
by multiple mechanisms (see PRC1 section below) that are not completely understood.
PRC2 recruitment to the chromatin has been studied extensively and yet many questions
remain unanswered.
PREs (Polycomb Response Elements) are regions at which both PcG and TrxG
proteins bind to chromatin (Ringrose L, 2003). PREs in Drosophila are better defined
than mammalian PREs as far as which proteins recruit PcG and TrxG proteins. In
Drosophila DNA sequence motifs allow for recruitment of the proteins PHO, Zeste, and
GAGA, which in turn recruit PRC2 (Mendenhall E, 2010; Wang L, 2004; Tolhuis B,
2006; Simon J, 1993). Recently, certain GC rich sequences have been shown to have
PRE properties in mammalian systems. (Mendenhall E, 2010). A region between
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HOXD11 and HOXD12 is a possible example of a PRE element to be defined in humans
(Woo C, 2011).
Activating chromatin marks prevent PRC2 from methylating H3K27me3.
Different studies have shown that the H3K36me3, H3K4me3, and H3K27ac marks
antagonize PcG protein functions (Tie F, 2009; Pasini, D 2010; Yuan W, 2011). One
report demonstrates that Suz12 can no longer bind H3K27me3 when an H3K4me3 or
H3K36me3 mark is present on histone H3 (Yuan W, 2011). Thus histone marks can
antagonize and prevent efficient PRC2 complex binding and/or activity.
Multiple chromatin marks can have a different outcome that individual marks
alone. A common example is when H3K4me3 and H3K27me3 are found together.
H3K4me3 and H3K27me3 are present together in the so-called bivalent domains which
are associated with regions poised for transcription. Pluripotent ES cells contain many
genome regions with bivalent domains that are resolved into H3K4me3 or H3K27me3
upon differentiation, depending on the cell type (Cui K, 2009). Bivalent domains are
associated with poised differentiation genes in ES cells and are found at the
transcriptional start sites of Sox, Fox, Pax, Irx, and Pou gene family members (Bernstein
B, 2005).
PRC2 activity is important in regulating the decision between stem cell selfrenewal and differentiation (Surface L, 2010; Kamminga L, 2006). A hypothesis that has
arisen in the field of cancer study is the idea of the cancer stem cell. This concept was
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proposed 150 years ago by Cohnheim and Durante (Wicha S, 2006). It is an attractive
hypothesis for two main reasons. Firstly, it goes a long way toward explaining why
cancers go into remission and then relapse. Secondly, it helps to explain why cancers
that are treated often relapse in a more aggressive form. Conventional cancer treatments,
such as chemotherapy or radiation, selectively kill rapidly proliferating cells. Cells that
are quiescent or slowly cycling have a survival advantage over proliferating cells. These
quiescent or slowly-cycling cells are subject to additional mutations. These escapees
may become resistant to additional rounds of treatment due to mutations that provide the
cells with resistance to apoptosis, leading to an aggressive relapsed disease.
MLL and its homologues have not only been implicated in leukemia but also in
many other cancers, such as prostate, diffuse large B-cell lymphoma, breast, and
pancreatic cancer (Grasso C, 2012; Lohr J, 2012; Ellis M, 2012; Mann K, 2012).
PRC1 complex
PRC1 is a complex comprised of four core proteins: hPC2 (CBX4), BMI1,
RING1A/B, and PH. Other orthologs of CBX4 include CBX2 (hPC1), CBX7, CBX8
(hPC3). The mechanism of PRC1 repression remains under investigation. PRC1 has
been shown to inhibit transcription, and it mediates ubiquitination of lysine 119 of the
histone H2A and its variants ( H2AK119ub) (King I, 2002; Sparmann A, 2006), which
may increase the binding of histone H1 to nucleosomal spacer DNA (Jason L, 2005).
Also RING1B has been shown to compact chromatin independently of histone
ubiquitination (Eskeland R, 2010). Finally CBX7, a component of PRC1, has been
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shown to recruit DNMTs to promoters of CBX7 target genes, promoting DNA
hypermethylation in cases of cancer (Mohammad H, 2009).
BMI1, which is part of the PRC1 complex, has been extensively studied for its
role in maintaining the stem cell phenotype. The stem cell phenotype includes the ability
to self renew, and to differentiate into many cell lineages (multipotency) upon
appropriate stimulation. In hematopoietic stem cells, BMI1 has been shown to be
required for maintaining the stem cells phenotypes (Park I, 2003). BMI1 and hPC2, two
of the components of PRC1, are found associated with MLL (Xia Z, 2003). BMI1 also
has a role in cancer and was shown to cooperate with c-MYC to promote the generation
of B and T cell lymphomas (Jacobs J, 1999). BMI1 has also been shown to be a
downstream target of c-myc (Sparmann A, 2006). Ring1a and Ring1b contain a RING
finger domain that functions as an E3 ubiquitin ligase. Ring1a/1b and BMI1 have
ubiquitin ligase activity specific to H2AK119ub. Bmi1 and Ring1A through H2A
ubiquitination plays an important role in HOX gene silencing (Cao R, 2005).
CBX8, a PRC1 component, has been shown to play a role in MLL-AF9
leukemogenesis (Tan J, 2011). Briefly, it was shown that CBX8 (also known as hPC3) is
necessary for transformation of MLL-AF9 cells. By knockdown or knockout of CBX8,
MLL-AF9-mediated transformation can be prevented; the expression of the HOX genes is
reduced in such knockout cells upon transduction of MLL-AF9. The investigators believe
that this phenomenon is independent of the PRC1 complex because if they knockdown
RING1B expression by shRNA, MLL-AF9 can still transform cells (Tan J, 2011). Also
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BMI1 has been shown not to be required for MLL-AF9 transformation, but loss of BMI1
in PLZF-RARα, and AML1-ETO trigger senescence and prevents transformation (Smith
L, 2011).
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Figure 5. Multiple domains of MLL function together to regulate MLL target gene
transcription.
The domains that are pertinent to this study are shown above. In brief, what has
been shown prior to this study is that HDAC1 binding to MLL is increased in the
presence of CYP33, which subsequently leads to deacetylation of MLL target genes.
CYP33 also has been shown to decrease H3K4me3 at MLL target genes. This mark is
placed by the SET domain of MLL. The mechanism by which CYP33 functions to lead
to decreased H3K4me3 is currently under investigation.
Also indicated in the above diagram are the proteins that compete for binding to
the PHD3 finger. CYP33, when bound, reduces the affinity of the MLL PHD3 for
H3K4me3. CYP33, when bound to MLL, promoters the recruitment of HDAC1, which
can then deacetylate appropriate residues on the histone tails or on other proteins. CBP, a
histone acetyltransferase, binds to the AD of MLL and can acetylate H3K18 and H3K27.
Also shown is the fusion protein, MLL-ENL, which is able to activate MLL target gene
expression, but is unable to bind CYP33 or to repress MLL target genes transcription, as
it lacks the PHD3.

CHAPTER III
MATERIALS AND METHODS
Cloning
pCEP4, pCEP4-CYP33, and pCEP4-CYP33 M were cloned by Dr. Peter Breslin,
Wei Wei, and Dr. Ute Osmers (Park S, 2010). Using these plasmids as a template, HACYP33 and HA-CYP33 M were cloned into the HA CMV vector using the following
strategy. HA- CYP33 and HA-CYP33 M were pcr amplified from pCEP4-CYP33 and
pCEP4-CYP33 M using primers containing Sal1 and Kpn1 restriction sites flanking the
coding sequence of CYP33 (Table 8). High fidelity Pfu DNA polymerase from
Stratagene was used to avoid mutations. After addition of buffer and dNTPs, the solution
was run on a BioRad Thermocycler (iCycler) using a program of 95oC. for 5 minutes for
a single cycle, then 35 cycles of 95oC., 60oC., and 72oC. for 45 seconds each, followed by
a 72oC. extension step for 7 minutes. TA cloning using 0.5µL of Taq Polymerase from
Promega and 1µL dATP was then performed at 72oC. for 30 minutes. The product was
then separated on a 1.8% agarose gel to check for the correct product size of 1400bp.
The 1400bp band was excised from the gel and DNA purification was performed using
the Promega Gel Extraction Kit. The excised band was subcloned into pGEMT.
Subcloning was achieved using 3μl of the PCR cloned KpnI/SalI CYP33 or CYP33 M
fragment a
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1µL of pGEMT, along with 1μl of T4 DNA ligase and 5μl of 2X ligase buffer from
Fermentas. Prior to cloning the insert from pGEMT into HA-CMV, the pGEMT plasmid
containing CYP33 or CYP33 M was cut with Sal1 to determine orientation and then sent
to an outside source for sequencing. Clones containing the correct sequence were then
cut with Kpn1 and Sal1. The Kpn1/Sal1 CYP33 or CYP33 M fragment was then ligated
into HA-CMV vector.
siRNA construction
siRNA’s were purchased using IDT’s predesigned DsiRNA. siRNA’s were
diluted using siRNA dilution buffer which is comprised of 30mM HEPES, 100mM
potassium acetate, in DEPC water pH adjusted to 7.5. The siRNA dilution buffer is then
filter sterilized and the siRNA were diluted to 100µM. siCYP33 (2) was used for MSA
cell knockdown and timecourse experiments. Both siCYP33 (1) and siCYP33 (2) target
the RRM domain of CYP33. The sequences for the double stranded RNAs are shown
below.
siCYP33(1)

5’-rArGrCrUrArUrCrGrArCrArArCrArUrGrArArUrGrArArUCT-3’
5’- rArGrArUrUrCrArUrUrCrArUrGrUrUrCrUrCrGrArUrArGrCrUrGrC3"

siCYP33 (2)

5’-rGrArGrArCrArUrCrArCrArGrArUrArUrUrCrArGrArUrUCC-3
5’-rGrGrArArUrCrUrGrArArUrArUrCrUrGrUrGrArUrGrUrCrUrCrCrA3'
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Table 3: Expression plasmids used in this study
Plasmid
pGEMT
HA CMV
HA-CYP33

Epitope

HA-CYP M

HA

pCEP4
pCEP4-CYP33
pCEP4-CYP33 M

FLAG
FLAG
FLAG

pIC-MLL-N
MLL RD-PHD

FLAG
FLAG, GAL4

HA
HA

Insert
N/A
N/A
AA 1-301
AA 1-301
(R191A,F196A)
N/A
AA 1-301
AA 1-301
(R191A,F196A)
AA 1-2665
AA 1088-1371,
1394-1630

Origin
Promega
Clontech
Subcloned from
pCEP4
Subcloned from
pCEP4
Invitrogen
Dr. Ute Osmers
Dr. Ute Osmers
Dr. James Hiesh
Dr. Keri Fair

Co-immunoprecipitation
In order to study the interactions of proteins, co-immunoprecipitation (CoIP) was
performed. Cells expressing the protein of interest were scraped off the culture dishes
after rising them with 1mL of PBS. After spinning down the cells at 1500 r.p.m. the
supernatant was removed. To lyse the cells 1mL of IPH buffer (50mM Tris-HCl pH 8.0,
150mM NaCl, 5mM EDTA, 0.5% NP40). Cells were incubated on ice for 1 hr.,
vortexing every 15 mins to break up the cells. The lysate could then be frozen at -20oC.
overnight and the protocol continued the next day. To clear the cellular debris, the
lysates were then spun down at 12,000 × g. at 4oC. for 30 minutes. The supernatant was
collected and placed in a clean microcentrifuge tube; the cellular debris was discarded.
The protein concentration was then quantitated using BCA or Lowry high methods.
Between 1mg to 2.5mg of protein was used for protein pulldown and 150μg to 200μg
was used as input.
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1mg to 2.5mg of the cell lysates were diluted to a final volume of 1mL using IPH
buffer. The lysates were precleared by adding 100μl of washed Protein A agarose beads
(Santa Cruz sc2001) for 10 minutes at 4oC. The lysates were then centrifuged at 12,000
r.p.m. for 30 seconds and the supernatant was placed into a 1.5mL microcentrifuge tube.
Sixty µL of washed Flag-M2 beads (Sigma) were added to the lysate. For Gal 4
pulldowns, 1μg of Gal4 Ab (see Ab table) was added along with 60µL of Protein A
beads. The mixture was then incubated for 2 hours to overnight at 4oC with gentle
rocking.
The Protein A/antibody complex was then collected by centrifuged at 12,000 × g.
for 30 seconds and the supernatant removed. Eight hundred μl of IPH was added to wash
the complex followed by rotation for 3 minutes and centrifugation. Three washes
allowed for non-specific interactions to be removed. The beads were then resuspended in
SDS-loading dye, followed by Western Blotting as described.
RNA extraction
Cells were detached from the culture dishes using 1 to 3 mL of Trypsin-EDTA
(Gibco). Cells were spun down at 2000r.p.ms and trypsin was removed. RNA was
extracted using Trizol® Reagent (Gibco). One mL of Trizol Reagent was added to the
cells. During timecourse experiments in which CYP33 was knocked down using siRNA,
or inhibited using CsA, once cell lysates were suspended in the Trizol Reagent they
immediately were placed in the -80oC. freezer, and the protocol was continued after all
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timepoints were collected. Freezing down the Trizol/cell mixture resulted in no reduction
of RNA quality.
One hundred μL of chloroform was added to the Trizol RNA mixture. After 2 to
3 minutes, Trizol/chloroform was centrifuged at 12,000 rpms in the cold room at 4 oC.
The upper liquid phase containing the RNA, was carefully removed as to not disrupt the
interphase layer. The RNA was then precipitated by using 250μL of 2-isopropanol.
Samples were incubated at room temperature for at least 10 minutes, and then they were
centrifuged at 12,000 r.p.m. for 10 minutes at 4oC. The supernatant was removed and
75% Ethanol-DEPC H20 was added to wash the pellet. The pellet was detached by
briefly vortexing. The pellet was then centrifuged at 6500 r.p.m. at room temperature for
5 minutes. The supernatant was removed completely and the pellet was air dried for 5
minutes, after which 25μL of DEPC H20 was added to the pellet and the solution was
placed at 55oC. for 10 minutes. RNA concentration was then determined using the
Nanodrop 2000c.
cDNA synthesis
Six μg of RNA was converted to cDNA using Applied Biosystem’s High Capacity
cDNA Reverse Transcription Kit (Part No: 4368814). RNA was treated with 3μL of
DNAseI (Fermentas Cat No) and 3μL of DNaseI Buffer in a total volume of 30μL.
Samples were incubated for 30 minutes at 37oC. Afterwards, 3μl of 50mM EDTA was
added, and the samples were mixed thoroughly and then incubated for 10 minutes at
65oC. to inactivate DNaseI.
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High capacity cDNA kit from AB was used for the reverse transcriptase reaction.
Briefly, 10× RT buffer, 25× dNTPs, 10× Random Primers, MultiScribeTM Reverse
Transcriptase, and of RNase Inhibitor, were mixed together to make a 2× master mix.
The 2× master mix was then added to the above DNAase1 treated reaction. For the
negative control, the same master mix was generated, minus the MultiScribeTM Reverse
Transcriptase.
Real Time PCR
cDNA or ChIP lysates were diluted 1 to 3 or 1 to 5 with ddH2O, and 7μL was
placed into a 96 well Dot #650-PCR plate already containing 18μL of a master mix
containing 12μL GoTaq® qPCR Master Mix (Cat # A6001), 1μL F/R primers, 0.25μL
CRX Reference Dye, and 4.75μL Nuclease-Free Water. RT-PCR sealing film
cengrifuging at 1000 r.p.m. in a Beckman GPR Centrifuge for 5 minutes, the plate was
inserted into an ABI7300 Real Time PCR machine and run 40 to 50 cycles. A
temperature of 60oC. was used for primer annealing unless otherwise indicated. The
dissociation or melting curve was obtained in order to show that the product was unique
and not a primer dimer; primer dimers would melt at a much lower temperature due to its
small size and GC content. Cycle threshold (Ct) values were obtained using either
manual or automatic setting using ABI7300 SDS system software. Relative values were
obtained using a ΔΔCt method. Standard deviations were calculated, taking into account
variation in both the standards and samples. To determine if changes in mRNA levels
reached significance, a student t test using GraphPad's student t test online was used.
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Western blot assays
IPH buffer (recipe shown in co-immunoprecipitation) was used to lyse cells in
order to isolate proteins for both Western Blotting and Co-IP. Proteins were quantified
by BCA assay (see below), and equal amounts of protein were loaded onto an SDSPAGE gel. Proteins were separated using SDS-polyacrylamide gel electrophoresis (SDSPAGE) and Tris-HCl-glycine running buffer. After electrophoretic separation, proteins
were transferred onto a PVDF membrane. CAPS buffer (10mM CAPS Sigma C2632 pH
to 11, 15% MeOH) or transfer buffer (25mM Tris, 200mM gylcine, 20% MeOH) were
used to transfer proteins depending on the protein of interest; CAPS was used for the
transfer of MLL or Jarid1b and transfer buffer was used for all other proteins. Using
CAPS buffer, transfer was accomplished at 25V. overnight followed by 70V. for 1 hour
using cold solutions at 4oC. Transfer for proteins under 200kD was conducted at room
temperature for 1 hour at 100V. After transfer, the membrane was placed in PBST (PBS
Gibco 0.05% Tween20) and 5% nonfat dry milk for one hour at RT to block non-specific
bands. After removing the blocking solution, PBST/2.5% milk was added along with the
appropriate primary antibody, followed by incubation overnight at 4oC. or 3 hours at
room temperature. The membrane was rinsed three times for 2 minutes each in TBST
followed by addition of the appropriate secondary antibody. The membrane was
incubated for 45 minutes in secondary antibody before being removed and then washed
in TBST for 5 minutes three times and then rinsed in TBS once for one minute before
detection with Supersignal ECL from Pierce. Signals were visualized using a FugiFilm
Intelligent Dark Box LAS 3000.
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Chromatin immunoprecipitation
Adherent cells, 293T or MSA, were trypsinized in 3mL Trypsin-EDTA 0.05%.
One mL was used for RNA analysis and the rest diluted to 10mL and fixed with
formaldehyde. Formaldehyde was added to a final concentration of 1% and the cells
were fixed for 10 minutes by shaking. To stop the reaction, 1mL of 1.25M glycine was
added and the solution was mixed by inversion. After 5 minutes, cells were spun down at
1750 r.p.m. for 5 minutes, then washed twice with ice-cold PBS and centrifuged at 4 oC.
at 1750 r.p.m. Supernatant was removed and the pellet was resuspended in 0.5mL Cell
Lysis Buffer (solutions for the ChIP protocol are described at the end of this section) plus
5µL of 100× protease inhibitor cocktail (Roche Complete Cat. No. 04 693 116 001) and
the solution was placed on ice for 15 minutes, with vortexing every 5 minutes. The
nuclear pellet was centrifuged at 1750 r.p.m. for 5 minutes and then lysed in 0.5mL of
Nuclear Lysis Buffer plus 5µL of 100× protease inhibitor.
The nuclear lysis was aided by sonication using a Branson Sonifier250 using one
of the protocols below. Sonication was empirically tested by taking individual cell lines
and sonicating them using various parameters in order to determine the optimal protocol
necessary to fractionate the DNA to between 200 and 1000 bp. Six second pulses were
performed for the indicated duration. Samples were placed on ice between replications to
prevent the heating of samples.
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Table 4. Sonication Condtions
Cell Line

Sonication protocol

HEK293

(Output 4) four rounds of 6 second pulses

MSA

(Output 4) eight rounds of 6 second pulses

MEF

(Output 5) three rounds of 6 second pulses

After sonication, solution was centrifuged at 10,000 r.p.m. at 4oC. for 10 minutes.
Twenty-five μL of undiluted sample was used for Input. Input was removed and frozen
at -20oC. to be used at a later time. Fifty μL was then diluted using 450μL of ChIP
Dilution Buffer plus 4.5μL of 100× protease inhibitors to a 2mL flat bottom
microcentrifuge tube. To the diluted sample, 5μL of Antibody and 20μL of Protein A
magnetic beads (Millipore Cat. 16-661) were added. The samples were then placed into a
50mL falcon tube and rotated at 4oC. overnight. The magnetic beads were pelleted using
a magnetic rack. The Protein A/Ab/chromatin complex was then washed with low salt,
high salt, LiCl, and TE buffer for 5 minutes, pelleting the complexes in between.
After the washes, all the supernatant was removed, and to both Input and samples
100μl of ChIP Elution Buffer plus 1μl of 10μM proteinase K was added. Samples and
Input were then incubated at 62oC. for 2 hours to reverse the crosslinking and to degrade
the protein. Samples were heated for 10 minutes at 95oC. to inactivate the Proteinase K,
and then cooled down to room temperature. Beads were removed by pelleting in the
magnetic rack, and the samples removed and placed into a microcentrifuge tube. DNA

55
purification kit from Molebio was used to extract the DNA. Fifty μL of TE was used to
elute samples, which were diluted either 1:3 or 1:7. Seven μl were used to evaluate a
number of target genes using real time PCR.
Table 5. ChIP solutions
low salt

0.1%
1.0%
2mM
20mM
150mM
high salt 0.1%
1.0%
2mM
20mM
500mM
LiCl
1.0%
1.0%
1mM
10mM
TE
10mM
1mM
Nuclear 1.0%
Lysis
10mM
Buffer
50mM
Cell
3mM
Lysis
10mM
Buffer
10mM
0.1%
ChIP
0.01%
Dilution 1.1%
Buffer
1.2mM
16.7mM
150mM

SDS (Sodium Dodecyl Sulfate)
Triton X-100
EDTA
Tris HCl pH 8.0
NaCl
SDS (Sodium Dodecyl Sulfate)
Triton X-100
EDTA
Tris HCl pH 8.0
NaCl
NP40
Deoxoycholic acid (Sodium Salt)
EDTA
Tris HCl pH 8.0
Tris HCl pH 8.0
EDTA
SDS
EDTA
Tris HCl pH 8.0
MgCl2
NaCl
Tris pH 7.4
NP40
SDS
Triton X-100
EDTA
Tris HCl pH 8.0
NaCl

ChIP solutions were made and then filtered through a 0.22μm vacuum sterile filter in
order to remove all contaminants.
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ATP cell viability and proliferation assay

Cell Titre Glo (Promega) assay was used to determine ATP levels in the cell after
CYP33 knockdown or over-expression. Eight hundred thousand MSA cells were
transfected overnight with siGFP or siCYP33 was using Lipofectamine 2000 at 4μl per
60mm dish. For over-expression studies, cells were transfected with pCEP4 vector,
CYP33, or CYP33 Mut using 10μl of Lipofectamine in a 60mm dish. Cells were
transfected for 12 hours, and afterwards MSA medium (DMEM/F12 Gibco) containing
transfection was removed and replaced by fresh medium. After 24 hours, cells were
trypsinized, and 5,000 cells were plated in a Falcon white opaque 96 well plate together
with 70μl of DMEM/F12 complete medium. Twenty-four hours later, the Cell Titre Glo
assay (Promega) was performed. Cells were incubated for 30 minutes at room
temperature with slow shaking to allow cells to reach RT. Cell Cell Titer Glo reagent
was prepared and stored at -20oC. until use; the reagent thawed and kept on ice during
use. The buffer and substrate were combined according to manufacturer’s protocol.
After thawing the reagent (buffer and substrate), 70μl of Cell Titer Glo reagent was added
to 70μl of medium for 10 minutes before the luminescence was detected using a
PolarSTAR Omega microplate reader.
Cell culture
The HEK 293T cell line was purchased from American Tissue Culture Collection
(ATCC) and was grown in DMEM (Gibco), 10% Fetal Bovine Serum (Gibco) and 1%
Penicillin/Streptomycin (Hyclone). Cells were maintained at around 50-60% confluency.
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The MSA cell line, a human thyroid carcinoma cell line, kindly provided by Dr. Shoji
Nakamori (Osaka National Hospital, Japan), was cultured in DMEM F/12 (1:1) high
glucose (GIBCO), supplemented with 10% FBS and 1% penicillin/streptomycin at 6070% cell density for routine maintenance. Mouse embryonic fibroblasts, that are wild
type for MLL, MLL+/+ or fibroblasts that lack a functional MLL, in which LacZ has been
inserted into the third exon of MLL (Yu, B 1995). MEFs were grown in DMEM
(GIBCO), supplemented with 10% FBS, 1% penicillin/streptomycin and 0.1mM βmercaptoethanol. Cell lines used in this study are shown below.
Table 6. Cell lines used in this study
Cell Lines (Obtained from)
293T
MEF MLL+/+ (S. Korsmeyer)

Reason Used/Methods
Cells are easy to transfect/CoIP
Can use cell line to determine MLLdependent effects/ChIP
See above/ChIP
Repressed HOX gene cluster/RT-PCR and
ChIP

MEF MLL-/- (S. Korsmeyer)
MSA

Table 7. Antibodies used in this study
Antibody
H3K27 acetylation
H3K27 trimethylation
H3K4 trimethylation
H3 Pan aceytylation
H3
Mouse IgG
Rabbit IgG
CYP33
BMI1
BMI1
HDAC1 clone E210

ChIP/CoIP/Western
ChIP
ChIP
ChIP
ChIP
ChIP
ChIP
ChIP
ChIP/CoIP
ChIP
Western
ChIP/CoIP

Company/Cat No
Millipore/07-360
Millipore/07-449
Millipore/07-473
Millipore/06-599
Abcam/ab1791
Millipore/12-371b
Millipore/ChIP Kit
Abnova/H00010450-A01
Millipore/17-664
Millipore/05-637
Millipore/05-614
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FLAG
HA-tag
ACTIN
HOXC9
MLL N
GAL4

Western/CoIP
Western/CoIP
Western
Western
Western
Western/CoIP

GenScript/A00013
Abcam/ab9110
MP/69100
Abcam/ab50839
Millipore/05-764
Millipore/06-262

Table 8. Primers used in this study
Human Primer Table
Primer Name
CDNK1B(P27)F
CDNK1B(P27)R
MYC F
MYC R
SIX1 F
SIX1 R
CCNA2 F
(CyclinA2)
CCNA2 R
(CyclinA2)
β-ACTIN F
β-ACTIN R
GAPDH F
GAPDH R
B2M F (beta 2
microglobulin)
B2M R
MEIS1 F
MEIS1 R
HOXA9 F
HOXA9 R
HOXC8 F
HOXC8 R
CYP33 F
CYP33 R
MLL F

RTPCR/ChIP
RT PCR
RT PCR
RT PCR
RT PCR
RT PCR
RT PCR
RT PCR

Sequence 5'-3'

RT PCR

CACGGGACAAAGCTGGCCTGA

RT PCR
RT PCR
RT PCR
RT PCR
RT PCR

CGTACCACTGGCATCGTGAT
GTGTTGGCGTACAGGTCTTTG
ATGGCAAATTCCATGGCACCGT
ATGGTGGTGAAGACGCCAGT
TGCTGTCTCCATGTTTGATGTATCT

RT PCR
RT PCR
RT PCR
RT PCR
RT PCR
RT PCR
RT PCR
RT PCR
RT PCR
RT PCR

TCTCTGCTCCCCACCTCTAAGT
CAGAAAAAGCAGTTGGCACA
TCATGCCCATTCCACTCATA
TCCCACGCTTGACACTCACACTTT
AGTTGGCTGCTGGGTTATTGGGAT
TGGAAACCTGAAGGAGATGTGGGT
AAACAGGGAAGGAGAGGAAGGCAT
TCCAGGCCAGTTTGGTCAGATGAT
CCGGCTTGTTCCCAATCTTGATGT
ATGTGGAAAGTGTGATCGCTGGGT

CCGGCTAACTCTGAGGACAC
CTTCTGAGGCCAGGCTTCTT
CCTACCCTCTCAACGACAGC
CTCTGACCTTTTGCCAGGAG
AGCTCCTGGCGTGGCCCATA
CGCGGAGGCCAAGGAAAGGG
ACTGTTGTGCATGCTGTGGTGCT
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MLL R
CDNK1A(P21) F
CDNK1A(P21) R
BMI1 F
BMI1 R
CDNK1B(P27)F
CDNK1B(P27)R
MYC F
MYC R
SIX1 F
SIX1 R
CCNA2 F
(CyclinA2)
CCNA2 R
(CyclinA2)
ACTIN F
ACTIN R
GAPDH F
GAPDH R
B2M F (beta 2
microglobulin)
B2M R
CYP33
CYP33
MLL
MLL
CYP33 Sal
CYP33 Kpn1

RT PCR
RT PCR
RT PCR
RT PCR
RT PCR
ChIP
ChIP
ChIP
ChIP
ChIP
ChIP
ChIP

TGCCGCTCAGTACAGTTCACACAA
GCAGACCAGCATGACAGATTT
GGATTAGGGCTTCCTGGA
CTGGTTGCCCATTGACAGC
CAGAAAATGAATGCGAGCCA
CCGGCTAACTCTGAGGACAC
ATACGCCGAAAAGCAAGCTA
TCCGCCCACCGGCCCTTTAT
TCAGCGCGATCCCTCCCTCC
ACCAGGTTGCCAGATTCGTTGGC
TGCCATTACTCATGCCCTCAAAG
CCTGCTCAGTTTCCTTTGGT

ChIP

ATCCCGCACTATTGAAATG

ChIP
ChIP
ChIP
ChIP
ChIP

TGCACTGTGCGGCGAAGC
TCGAGCCATAAAAGGCAA
TACTAGCGGTTTTACGGGCGCACGT
TCGAACAGGAGGAGCAGAGAGCGA
AGACTTCCCAAATTTTGCCATCCTA

ChIP
ChIP
ChIP
ChIP
ChIP
Cloning
Cloning

AAAGGCCTGAAATGTTAGTGTTGAGT
TGAACCAGGAGGACGGCGAG
TGAACCTTGGGGGCAAGTGG
GCGTCCCGGGAACGTGTGTAA
GATGGAGGCGTAGGGAGCCG
GTCGACCGCCACCACCAAGCGCGTCTTGTA
GGTACCCACCCTCGGTGCTGCCTCCT

Mouse Primer table
Primer Name
Actin F
Actin R
Cyp33 F
Cyp33 R
Mll F
Mll R
Cdnk1b(p27) F

RT-PCR/ChIP
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR

Sequence 5'-3'
GGCTGTATTCCCCTCCATCG
CCAGTTGGTAACAATGCCATGT
CATCAAGATTGGGAACAAGCCAGC
AAGCTGCTTCCCTTGAAGCCAAAG
GCATCGATGACAACCGACAGTG
CACAGCCATATGCACATTCTTC
GAACTAACCCGGGACTTGGAGAAGC
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Cdnk1b(p27) R
HoxA9 F
HoxA9 R
Cyp33 F
Cyp33 R
Mll F
Mll R

RT-PCR
RT-PCR
RT-PCR
ChIP
ChIP
ChIP
ChIP

TAACCCAGCCTGATTGTCTGACGAG
TACTATGTGGACTCCTTCCTGC
TTCCACGACGCACCAAACAC
CCCGACCTAAGGGGAGGGGC
AGGCCCAGCAAGCCCTCCAT
TTCCCTCCAGGCCCTGTCCG
TCGGCCTCTGCCACCTCCTC

Table Legend: RT PCR primers were designed spanning introns when possible to aviod
DNA contamination. ChIP primers were designed to known promoters. For less
established promoters the region upstream of the transcription start site was amplified.
CsA or 5-azacytadine treatment
MSA cells were treated with concentrations of 5-Azacytadine (5-Aza) for 72
hours, replacing the medium and 5-Aza every 24 hours. A concentration of 500 nM,
250nM, or 5μM 5-Aza was used. These concentrations were determined empirically by
using serial dilutions starting from 500μM. Cells were treated at 90% confluency with 5Aza. After 48 hours, cells were replated at 40% confluency. After 96 hours, cells were
harvested and RT PCR was performed to determine mRNA levels of MLL target genes.
MSA cells and MEFs were treated with Cyclosporin A (CsA) (Sigma) to a final
concentration of 5uM or 10μM for the indicated timepoints before cells were trypsinized
and collected in Trizol Reagent for RNA isolation. Treatment with CsA to determine
mRNA levels for MLL target genes independent of oscillation proceeded for 96 hours,
with replacement of CsA every 24 hours.
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Dectection of senescence associated β -galactosidase (SA β-gal)
X-Gal at pH 6 detects endogenous β-galactosidase and is used as a marker for
cellular senescence.Cells were washed twice with PBS before being fixed in 2%
formaldehyde and 0.2% glutaraldehyde diluted in PBS to cover the cells for 3-5 minutes.
Afterwards the cells were washed with PBS to remove the fixing solution. Staining
solution consisted of 1mg/ml X-Gal dissolved in dimethylformamide, 40mM of citric
acid/sodium phosphate buffer at pH 6.0, 5mM potassium ferrocyanide, 5mM potassium
ferricyanide, 150mM sodium cloride, and 2mM magnesium chloride. The pH of the
citric acid/Na phosphate buffer is crucial for the dection of SA β-gal. Cells were
incubated at 37oC. in a non-CO2 incubator. Blue color is detected after 12 to 16 hours
after incubation. X-Gal at pH 6 detects endogenous β-galactosidase and is used as a
marker for cellular senescence.
Proliferation Assay
MSA cells were transfected using Lipofectamine 2000 with vector alone (pCEP4),
pCEP4-CYP33, or pCEP4-CYP33 M for over-expression and siGFP (control) or with
two siRNAs specific for CYP33-labeled siCYP33 (1) siCYP33 (2) that target the RRM
domain. Twelve μg of DNA for over-expression or 100nM for siRNA were used. Cells
were then counted and replated daily with fresh medium for 9 days (DMEM/F12).
BCA assay for protein
The Pierce BCA Protein Assay Kit was used to determine protein concentration
for Western Blots and Co-IPs. A standard curve using BSA was created using varying
concentrations ranging from 0μg to 80μg of protein and diluted to 100μL with H20 into a

62
5mL Falcon polystyrene round bottom tube. Five μl of unknown protein sample was also
added to a clean 5mL tube and diluted to 100μL with ddH20. A master mix of the
working reagent was made by the addition of 50:1 Reagent A to Reagent B and vortexed
until well mixed. Two mL were then added to each standard and sample and the tubes
were placed at 37oC. for 30 minutes. After 30 minutes, samples were placed in a 1 cm
cuvette and standards were read on a Beckman DU530 Life Science UV/Vis
spectrophotometer at 562nm wavelength in order to create a standard curve. After the
generation of a standard curve, samples were read.
Transfection of plasmids and siRNA
Transfection of plasmids and siRNA was conducted using Lipofectamine 2000
reagent. Twelve μg of DNA or 100nM of siRNA were used for transfection. For
transfection, 0.8 million cells were plated in a 60mm dish for siRNA, or 2 million cells
for a 10cm dish in DMEM/12 complete (see cell culture section). When the cells were
attached, 4μl Lipofectamine 2000 for siRNA or 20μl for plasmids, along with the
corresponding DNA, was added. For example, for pCEP4, CYP33, and CYP33 M, 12μg
of DNA was added to 1.5mL DMEM/F12 in a 15ml Falcon tube. Twenty μl of
Lipofectamine 2000 was added to 1.5ml of DMEM/F12 in a 15ml Falcon tube. Both
DNA sample and solution containing Lipofecatmine 2000 were vortexed for 5 seconds.
After 5 minutes, DNA and Lipofectamine were combined. The solution was vortexed for
5 seconds and samples were incubated at room temperature for 30 minutes before being
added drop wise onto cells. After 12 hours, medium was replaced with fresh media.
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Cell cycle analysis
MSA cells were removed from 10cm plates using Trypsin EDTA 0.05%. After
centrifuging the cells at 2500 r.p.m. for 5 minutes, the trypsin solution was removed and
cells were washed once with PBS. The cell pellet was loosened and 1mL of 70 % ice
cold EtOH was added drop wise while vortexing. The cells were fixed for 30 minutes on
ice. The cell pellet was then centrifuged at 2000 r.p.m. for 5 minutes. The pellet was
again washed with 2mL of PBS and centrifuged at 2000 r.p.m. The supernatant was
removed and 0.25mL of RNAse A in PBS was added (final concentration of 20μg/mL).
Cells were incubated at 37oC. for 15 minutes. The pellet was then cooled down for 5
minutes. After this cool down period, 0.25mL of PI in PBS (final concentration of
50μg/mL) was added. The tube was wrapped in foil and kept dark for 30 minutes. Flow
cytometry of the PI-stained cells was performed and DNA content was determined.

CHAPTER IV
RESULTS
Modulation of cellular CYP33 concentration leads to a change in expression of MLL
target genes, and a subsequent change in H3 acetylation
The cyclophilin domain of CYP33 contains an enzymatic activity that promotes
isomerization of prolyl-peptide bonds between their cis and trans conformation: cis-trans
prolyl isomerase (PPIase) activity. Both deletion of the cyclophilin domain or inhibition
of the PPIase activity by Cyclosporin A (CsA) have been previously shown to render
CYP33 incapable of reducing HOXC8 transcription (Fair K, 2001; Anderson M, 2002;
Park S, 2010). CsA treatment inhibits the recruitment of HDAC1 to the RD of MLL in
the presence of over-expressed CYP33 (Koonce M, 2004). Due to the indiscriminate
nature of PPIase inhibition of all cyclophilins by CsA, a more specific means of testing
the function of the CYP33 PPIase activity was needed. Therefore a CYP33 PPIase
mutant (CYP33 M) was created to test this hypothesis. CYP33 M was a mutation
generated by Dr. Peter Breslin, S.J., in a plasmid encoding CYP33. The mutant CYP33
protein was shown to be enzymatically dead in a cis-trans prolyl isomerase activity assay
(Breslin, P and Schultz, R unpublished results). CYP33 M contains mutations in two
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residues lying in the active site of the cyclophilin domain that are critical for its
enzymatic activity (R191A and F196A) (Fig 9). These amino acid residues were chosen
for modification based on homology of the amino acid sequence of the CYP33
cyclophilin domain to that of cyclophilin A (CYPA). Mutations of the corresponding
residues in CYPA render the protein enzymatically inactive, retaining less than 1% of
wild-type activity (Zydowsky, L 1992).
In order to confirm that CYP33 was overexpressed or knocked down, the protein
and mRNA levels of CYP33 in MSA cells were tested by Western Blot and quantitative
PCR respectively. A six-fold increase or reduction of CYP33 protein levels was
observed based on densitometric analysis, compared to ACTIN protein levels (Figs. 6A,
6B). The Western Blot showed a similar trend to that of the CYP33 mRNA levels (Figs.
6C, 6D). Knockdown of CYP33 in MSA cells leads to increased expression of MLL
target genes CDNK1B, MYC, and SIX1, whereas over-expression of CYP33 leads to a
decrease in MLL target gene expression (Figs. 6E, 6F). Surprisingly, the expression of
the housekeeping genes ACTIN and GAPDH, which are not known targets of MLL, also
increased upon CYP33 knockdown, and were repressed upon CYP33 over-expression
(Figs 6E, 6F).
ChIP was conducted in order to determine if, upon knockdown of CYP33,
changes occurred in histone modifications, H3ac (K9ac and K14ac), H3K27ac and
H3K27me3 (Figs. 7, 8) at the chromatin of the affected genes. In order to obtain a more
accurate picture of how the histone modification marks change upon over-expression or
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Figure 6. Modulation of CYP33 levels leads to changes in MLL target gene
expression.
Either siGFP, siCYP33(2) (A,C,E) or pCEP4, pCEP4-CYP33, or pCEP4- CYP33
M (Table 3) (B,D,F) were transfected into MSA cells for 36 hours (siRNA), or 48 hours
(CYP33 over-expression). RT-PCR and Western Blots were used to confirm CYP33
knockdown or CYP33 over-expression. Relative band intensity estimated by average
densitometry is shown below the Western blots and represents three independent
experiments. Real time RT-PCR was conducted to determine mRNA levels in overexpressed or knocked down cells. Standard deviations are from triplicate real-time PCRs.
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knockdown of CYP33, the marks were normalized first to total H3 levels before the
modifications are compared between the controls and treatments. Two acetylation
antibodies were used: a pan acetylation antibody (H3ac) which recognizes histone tails
with the dual marks of H3K9ac and H3K14ac, and an antibody against H3K27 acetylated
histone tails.
Upon over-expression of CYP33, H3K27ac decreases at the CDNK1B, MYC,
SIX1 and ACTIN promoters (Fig. 7C). At the MYC, CDNK1B, and GAPDH promoters,
over-expression of CYP33 M does not significantly decrease H3K27ac compared with
the vector control indicating that the PPIase activity is important for reduction of
H3K27ac (Fig. 7C). Upon over-expression of CYP33 M in MSA cells, there is a
decrease in H3K27ac at the SIX1 and ACTIN promoters compared to the vector control,
but not as strong a decrease as upon CYP33 wild-type over-expression (Fig. 7C). Upon
knockdown of CYP33, MYC, SIX1, P27, and ACTIN promoters show a significant
increase of H3K27ac. Only H3K27ac at the GAPDH promoter doesn't increase. This
lack of increase may be due to an already high level of H3K27ac at the GAPDH
promoter. Therefore, further inhibition of CYP33, by knockdown does not increase
H3K27ac at the GAPDH promoter. For all promoters tested, H3K27me3 does not
significantly change upon CYP33 over-expression or knockdown (Figs. 7B, 7D). In
MSA cells at the promoters tested, the levels of H3K27me3 is very low comparable to the
IgG control.
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Figure 7. Modulation of CYP33 levels change H3K27ac at several gene promoters
while H3K27me3 remains low.
(A,B) siGFP, siCYP33(2), or (C,D) pCEP4, pCEP4-CYP33, or pCEP4-CYP33 M
were transfected into MSA cells. ChIP was conducted in MSA cells 36 hours after
transfection for siRNA or 48 hours after transfection for CYP33 over-expression, as this
was when it was observed that knockdown or over-expression led to a increase/decrease
of MLL target genes. ChIP was conducted on MSA samples using H3K27ac or
H3K27me3 specific antibodies. H3K27ac level change at the GAPDH promoter does not
reach significance upon CYP33 knockdown. Shown is one of three representative
experiments, and error bars shown are standard deviations +/- of triplicate PCRs.
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Figure 8. Modulation of CYP33 levels also leads to changes in H3ac levels.
siGFP, siCYP33(2), pCEP4, pCEP4-CYP33, or pCEP4-CYP33 M were
transfected into MSA cells similar to Figs. 11 and 12. ChIP was conducted in a similar
manner to Figure 7 but using α-H3ac (H3K9 and H3K14) antibody. Shown is a
representative of two independent experiments.
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Global H3ac (H3K9, H3K14) was also tested to determine if it decreases with
CYP33 over-expression as was shown in previous reports (Wang, Z 2010, Park, S 2010).
H3ac, like H3K27ac, increased upon the knockdown of CYP33 (Figs. 7A, 8A). Upon
CYP33 over-expression, H3ac decreases slightly or remains the same. CYP33 and
CYP33 M overexpression reduces H3ac at the SIX1 and GAPDH promoters, which is not
in accordance with the RT-PCR data obtained. H3ac is not as changed upon CYP33
over-expression as H3K27ac (Figs. 8F, 10B). Upon knockdown of CYP33, however,
H3ac shows a greater increase than H3K27ac at CDKN1B, MYC, SIX1, and GAPDH
promoters (Figs. 7, 8).
Over-expression of CYP33 increases recruitment of HDAC1 and BMI1 to the RD
domain of MLL in a PPIase-dependent manner
In order to test the interaction of MLL with CYP33 and its dependence on the
CYP33 PPIase activity, a Co-IP experiment using Flag tagged MLL-N, and HA tagged
CYP33 and CYP33 M was performed. Domain maps of the CYP33, CYP33 M, and
MLL constructs that were used in the CoIP experiments are shown (Fig. 9A).
Before conducting the CoIPs, the abilities of CYP33 and CYP33 M to repress the
MLL target genes HOXC8 and MYC were again confirmed in the HEK293T cell line by
over-expressing CYP33 or CYP33 M and conducting real time RT-PCR to measure
HOXC8 and MYC mRNA levels (Fig. 9B). Over-expression of CYP33 can downregulate MYC and HOXC8 transcription (Fig 9B). Upon over-expression of CYP33 M,
HOXC8 mRNA is expressed at a level close to that of the vector alone, whereas MYC
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Figure 9. The PPIase activity of CYP33 is necessary to decrease the expression of
MLL target genes HOXC8 and MYC upon CYP33 over-expression.
A) Schematic of the over-expression constructs used in Figures 10 and 11.
CYP33 contains two domains, an RRM domain and a cyclophilin domain, separated by a
spacer that is evolutionarily conserved. The MLL protein contains many domains
including but not limited to the repression domain colored red and the PHD fingers
shaded in green. The PHD fingers are separated by an atypical bromodomain (pink).
The GAL4 construct contains only the repression domain (RD) and the first three plant
homeodomain fingers (PHD fingers) amino acid residues 1088-1371 and 1394-1600. B)
pCEP4 vector, pCEP4-CYP33 or pCEP4-CYP33 M was transfected into 293T cells.
RNA was extracted 48 hours after transfection and real-time PCR was performed using
the ΔΔCt method using B2M as a control. HOXC8 and c-MYC are two representative
MLL target genes that show down-regulation upon CYP33 over-expression, but they are
not down-regulated by CYP33 M over-expression. Error bars show +/- standard
deviation for triplicate PCRs.
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mRNA appears to have increased above that of the vector alone (Fig. 9B) suggesting that
CYP33 M may act in a dominant negative manner by replacing the endogenous CYP33
in its complex with MLL. These results confirm previous published data, which
conclude that the PPIase activity of CYP33 is necessary for MLL target gene repression
(Anderson, M 2001, Fair, K 2002, Xia, Z 2003, Park, S 2010, Wang, Z 2010).
Co-IP experiments were also performed to determine whether the recruitment of
BMI1 and HDAC1 proteins to MLL is dependent on the PPIase activity of CYP33. A
plasmid expressing Flag-tagged MLL-N (amino acid residues 1-2665) was transfected
together with an empty vector (HA-CMV), or expression plasmid constructs for HACYP33 or HA-CYP33 M in HEK293T cells. Flag-tagged MLL was immunoprecipitated,
and the precipitate probed using α-HDAC1 or α-BMI1 antibodies in immunoblots. As is
shown in Fig. 10A, CYP33 over-expression enhances the recruitment of HDAC1 and
BMI1 to MLL-N (Fig. 10A). These results confirm previous findings that CYP33
enhances HDAC1 recruitment to MLL (Xia, Z 2003) and extends these observations to
BMI1. Jarid1b, an H3K4me3 demethylase, and MLL were also blotted after
immunoprecipitation (Fig. 10B). Interestingly, Jarid1b was also shown to bind to MLL
(Fig. 10B). However, Jarid1b recruitment to MLL-N, did not increase upon CYP33 overexpression.
By over-expressing either CYP33 or CYP33 M, it is possible to determine if the
recruitment of CYP33 is dependent upon the cis-trans prolyl isomerase activity of
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Figure 10. Recruitment of HDAC1 and BMI1 to the MLL N is increased by CYP33
over-expression in a PPIase dependent manner.
A) pIC-MLL N-terminal construct, along with either HA-CMV (vector), HA
CYP33 or HA CYP33 M was transfected into 293T cells. MLL-N is flag-tagged at its Nterminal end (Figure 9). Forty-eight hours after transfection, cells were harvested and
lysed. Input (INP) blots are indicated to distinguish them from immunoprecipitated blots
(IP:FLAG). (IB) Immunoblot denotes the antibody used in western detection The
HDAC1 and BMI1 blots are representative of three independent experiments. B) Flag
pulldowns followed by blotting for HA was conducted to shown equal recruitment of
HA-CYP33 and HA-CYP33 M to the MLL PHD3. C) Quantification of HDAC1 in input
versus HDAC immunoprecipitated was conducted using Multigauge Software that is a
companion to the FujiFilm detection device. Error bars are standard deviations and the p
value between CYP33 and CYP33 M is highly significant for both HDAC1 (p=.0169)
and BMI1 (p=.0009) using the Student t test.
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CYP33. Binding of CYP33 M to MLL-N is similar to the binding of CYP33 as shown
by HA antibody (Fig. 10B). The recruitment of either HDAC1 or BMI1 to MLL-N is not
increased when CYP33 M is over-expressed, compared with expression of the vector
control. The relative amounts of HDAC1 and BMI1 precipitated with MLL-N were
quantified from three independent experiments (Fig. 10C). CYP33 increases HDAC1
and BMI1 recruitment to MLL-N in a PPIase dependent manner.
In a recent paper (Wang, Z 2010), it was proposed that isomerization of a prolyl
bond residue (H1628-P1629) that lies between the PHD fingers and the bromodomain of
MLL, is necessary for the bromodomain to move away from the CYP33 biding site on
the MLL PHD3. If this hypothesis is correct, the CYP33 PPIase activity may only be
necessary for binding of CYP33 to MLL-N, but may not be necessary for recruiting
HDAC1 and BMI1 to MLL. In order to determine if the CYP33 PPIase activity is
necessary to recruit HDAC1, or BMI1 to the RD of MLL independently of the
bromodomain, a construct that contains only the RD and the PHD fingers, but not the
bromodomain, was used for Co-IP. This construct N- terminal tagged with a Gal4
domain was used to test the recruitment of HDAC1 and BMI1. In the absence of the
bromodomain, HDAC1 recruitment still requires the PPIase activity of CYP33, whereas
BMI1 binding to MLL no longer requires the CYP33’s PPIase activity (Fig. 11A).
Even when using the smaller construct MLL RD-PHD, HDAC1 bind MLL in a
PPIase-dependent manner, suggesting that the PPIase target is either within the RD, the
PHD finger domain, or HDAC1 itself. This confirms previous data which showed that
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Figure 11. CYP33 over-expression results in recruitment of HDAC1 and BMI1 to
the RD domain of MLL.
A, B) The GAL4-FLAG RD PHD , along with either HA-CMV (vector), HACYP33 or HA-CYP33 M was transfected into 293T cells. (UNT) denotes untransfected
293T cells. The GAL4-FLAG-RD PHD is tagged at its N-terminus (Figure 9). Fortyeight hours after transfection, cells were harvested and lysed. Input (INP) blots are
indicated to distinguish them from immunoprecipitated blots (IP:GAL4). (IB)
Immunoblot denotes the antibody used in western detection Anti-GAL4 was used for
immunoprecipitation and either HDAC1 or BMI1 were immunoblotted. Representative
of two independent experiments.
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CYP33 overexpression was able to recruit HDAC1 to the RD-PHD finger domain (Xia, Z
2003). In contrast, BMI1 binding to the RD-PHD MLL no longer shows a dependence
on the PPIase activity of CYP33, but is still increased upon CYP33 or CYP33 M
overexpression (Fig. 11). This was surprising, as this suggests that for BMI1, another
function of CYP33, separate from its PPIase activity is involved in regulating binding of
BMI1 to the RD of MLL.
The recruitment of BMI1 and HDAC1 to chromatin at MLL target genes does not
change upon CYP33 or CYP33 M over-expression
ChIP was used to test whether CYP33 promotes the recruitment of HDAC1 and
BMI1 to the chromatin of MLL target genes (Fig. 12). Surprisingly, BMI1 and HDAC1
binding to the MYC, CDNK1B, or SIX1 promoters does not change upon CYP33 or
CYP33 M overexpression. The recruitment of HDAC1 and BMI1 is also not dependent
upon the PPIase activity of CYP33, since at the MYC, CDNK1B, and SIX1 promoters, the
recruitment of these proteins after CYP33 M over-expression is very close to vector
control. BMI1 binding does not change either upon CYP33 knockdown. HDAC1
recruitment on the other hand, is decreased upon knockdown of CYP33 at MYC and
CDNK1B promoters, but not at SIX1 promoters. This inconsistency between the Co-IP
data and the ChIP data will be explained in more detail in the discussion section.
Knockdown of CYP33 by siRNA or PPIase activity inhibition by CsA, leads to
oscillations in MLL target gene expression
During knockdown of CYP33 it was observed that, depending upon the timepoint
at which the cells were collected after siRNA transfection, the expression of MLL target
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Figure 12. Recruitment of BMI1 and HDAC1 to the chromatin does not increase
upon CYP33 over-expression.
CYP33 was either over-expressed or knocked down in MSA cells using the
indicated plasmids as previously described in Fig 6. 48 hours after overexpression or 36
hours after knockdown ChIP was conducted to test for BMI1 or HDAC1 recruitment to
the chromatin using α-HDAC, α-BMI1 or an antibody against mouse IgG as a negative
control.
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CDKN1A CDKN1B

Figure 13. Knockdown of CYP33 leads to increased MLL target gene mRNA
expression.
Following 24 hours or 96 hours after transfection of siGFP or siCYP33 were
transfected as described in Fig 6, RNA was collected and real-time RT PCR was
conducted to explore whether knockdown of CYP33 by siRNA increases MLL target
gene expression.

81
genes, including CYP33, was either increased as expected, or decreased, when compared
to the control (Fig. 13). After 96 hours, CYP33 is repressed two-fold, as are MYC and
CDNK1B. Expression of CDKN1A, a gene repressed by MYC, is increased after 96
hours. This, along with inconsistencies in CYP33 knockdown, led us to conduct a more
detailed timecourse experiment to explore whether knockdown of CYP33 by siRNA led
to oscillations in MLL target gene expression.
In three independent experiments, oscillations showed a regular period were
observed in the expression of MLL target genes, but the periodicity of these oscillations
differed in each experiment (Fig. 14). The more intense the knockdown of CYP33, as
shown by RT-PCR, the longer the period and the higher the peaks and valleys of CYP33
and MLL target genes. After finding that there were oscillations in CYP33, MLL and
MYC gene expression, their target genes expression was studied to determine whether it
oscillated as well. As indicated in Fig. 14, both the expression of MLL target genes and
c-MYC target genes, such as BMI1 and CDKN1A, oscillate in response to changes in
CYP33.
In order to test whether the inhibition of the PPIase activity of CYP33 also led to
oscillations in gene expression, MSA cells were treated with CsA. A timecourse
experiment was set up to determine the optimal time for CsA treatment of MSA cells
(Fig. 15A). Based on data from the MEF cells, a concentration of 10 μM CsA was
selected for the experiment as this gave the most robust increase of MLL target genes.
The shortest time possible that yielded an increase in MLL target gene expression was

82
A

CYP33

1.2
0.8

Fold change in mRNA
expression

0.4
0
siGFP siCYP siCYP siCYP siCYP siCYP siCYP
12h

12h

24h

36h

48h

60h

72h

1.2
0.8
0.4
0
siGFP siCYP siCYP siCYP siCYP siCYP siCYP
12h

12h

24h

36h

48h

60h

72h

1.2
0.8
0.4
0
siGFP siCYP siCYP siCYP siCYP siCYP siCYP
12h

12h

24h

36h

48h

60h

72h

1.5

CYP33

B
5
4

MYC

3
2

Fold change in mRNA
expression

1
0
siGFP siCYP siCYP siCYP siCYP siCYP siCYP siCYP siCYP
12h

10
8
6
4
2
0

12h

24h

36h

48h

60h

72h

84h

96h

BMI1

1
0.5
0
siGFP siCYP siCYP siCYP siCYP siCYP siCYP siCYP siCYP

siGFP siCYP siCYP siCYP siCYP siCYP siCYP siCYP siCYP

12h

4
3

12h

24h

36h

48h

60h

72h

84h

CDKN1A

2
1
0
siGFP siCYP siCYP siCYP siCYP siCYP siCYP siCYP siCYP
12h

12h

24h

36h

48h

60h

72h

84h

12h

96h

96h

3.5
3
2.5
2
1.5
1
0.5
0

12h

24h

36h

48h

60h

72h

84h

96h

MLL

siGFP siCYP siCYP siCYP siCYP siCYP siCYP siCYP siCYP
12h

12h

24h

36h

48h

60h

72h

84h

96h

83
Figure 14. Knockdown of CYP33 by siRNA leads to oscillations in expression of
MLL target genes.
A) siGFP (control) or siCYP33(2) were transfected into MSA cells. The x-axis
shows time in hours after transfection. At each timepoint, siGFP was set as 1. Results of
three independent experiments are shown. B) The expression of target genes of MLL or
c-MYC is shown for experiment 1 from part A. Time is indicated as hours after the start
of transfection. Each time-point was normalized relative to siGFP at the corresponding
time, although only siGFP at 12 hours is shown for simplicity. Shown is a representative
of three experiments.
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used. A short time was used because CsA is a general inhibitor of cyclophilins and has
off-target effects that may influence the results. MLL target gene expression increased
after only 6 hours of treatment, and this was the treatment time used in subsequent MSA
treatments. After 6 hours, a 100-fold increase over the EtOH (control) was observed for
CDNK1B gene transcription, and a 20-fold increase over control was seen for MYC gene
transcription (Fig. 15B). The levels quickly diminished and returned to near control
levels by 18 hours. After 42 hours, an additional increase of 10-fold was seen for MYC
showing an oscillation of its mRNA transcription levels, with diminishing amplitude.
The oscillations of CDNK1B differed in that after 30 hours, a robust decrease in
CDNK1B was seen when compared to control. With time, CDNK1B levels recovered,
and after 72 hours an increase is again seen compared to control.
Both increase and decrease of CYP33 protein levels causes decreased cell growth in
MSA cells.
It was observed that upon CYP33 over-expression or knockdown, MSA cell
growth was decreased. To quantify the decreased cell proliferation, viable cells were
counted and Cell Titre-Glo, an assay to measure cellular ATP levels, was conducted.
One hundred thousand cells were transfected with either CYP33, CYP33 M or 2×104
cells were transfected with siRNA to GFP or CYP33. Two separate siRNAs, targeting
different nucleotide sequences of CYP33 were used to discount off-target effects. Every
other day cells were counted using Trypan Blue exclusion in order to determine live cell
numbers, which were subsequently re-plated. As is shown, a decrease in cell growth was
observed up to 5 days after transfection (Fig. 16A). After 5 days cells regained the ability
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Figure 15. Treatment with CsA (a cyclophilin prolyl isomerase inhibitor) leads to
oscillations in the expression of MLL target genes.
A) MSA cells were treated for the indicated periods of time with CsA, followed
by RNA collection and RT-PCR. B) RNA was collected and RT-PCR was performed
after 6 hours of CsA treatment. C) Cell were washed to remove CsA, and then collected
every 12 hours, 18h, 30h, 42h, 54h, 66h, 78h. After collection, RNA was prepared and
RT-PCR was conducted. CsA treatment was normalized to EtOH control at each
timepoint, but only EtOH control at 18H is shown for simplicity. c-MYC and CDNK1B
are MLL target genes. BMI1 and CDKN1A are c-MYC target genes. Expression MLL
and CYP33 were also shown to oscillate upon inhibition of CYP33 by CsA. This is a
representative of two independent experiments.

87
to grow at a rate similar to control cells. Therefore, either over-expression of WT CYP33
or knockdown by siRNA causes decreased cell growth. In addition to cell growth,
cellular morphology changed after CYP33 knockdown, with cells becoming flatter and
having a greater number of projections (Fig. 16B).
In order to further quantify this phenomenon which is also seen in 293T cells,
MSA cells were transfected with either vector (pCEP4), CYP33, or CYP33 M expressing
plasmids. Also, siGFP or siCYP33 were transfected into MSA cells. ATP detection was
conducted using a Cell Titre-Glo assay according to the manufacturer’s specifications.
The Cell Titre-Glo assay is useful for estimation of ATP levels within the cell and thus
can be used as a surrogate marker of cell viability and/or cell proliferation. A decrease in
ATP levels was observed in cells over-expressing WT CYP33, but not in cells overexpressing CYP33 M (Fig. 16C). Increasing CYP33 protein levels by over-expression
decreased ATP levels more than two-fold, whereas ATP levels remained the same upon
CYP33 M over-expression. Upon CYP33 knockdown by siRNA in MSA cells, a
slowdown in cell growth was also observed, but no change in ATP levels between siGFP
and siCYP were observed (Fig. 16A).
Consequently CYP33 levels inversely correlate with ATP levels within a cell
upon CYP33 over-expression. The decreased ATP levels correlated with changes in cell
proliferation, both being dependent upon CYP33 PPIase activity. Upon knockdown of
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Figure 16. Growth of MSA cells is sensitive to over-expression or down-regulation
of CYP33.
A,B) Measurement of cell growth by counting cells upon CYP33 over-expression
or knockdown, by two different siRNAs (siCYP33 (1), siCYP33 (2)). Also pCEP4,
CYP33 or CYP33 M were transfected into MSA cells. Cells were plated in 3 separate
plates and counted. Standard deviations are shown. C) Cell Titre-Glo assay (Promega).
This assay assesses the level of ATP within the cell which is a surrogate marker of cell
growth/death. As shown, knockdown does not change the levels of ATP within the cell,
whereas over-expression of CYP33 decreases ATP levels. The standard deviation of
three independent experiments is shown. D) PI staining followed by flow cytometric
analysis.
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CYP33 by siRNA, there is also a decrease in cell proliferation but no corresponding
decrease or increase in ATP levels. A decrease in ATP levels is not likely due to
apoptosis, as PI staining followed by FACS analysis showed no significant sub-G1 cell
population (Fig. 16D).
It was also observed that upon siRNA knockdown of CYP33, cells became flatter
and larger, with longer projections, although this was not quantified. These are common
characteristics of senescent cells. In order to test whether knockdown of CYP33 causes
an increase in senescence, senescence associated β-galactosidase (SA β-gal) assay was
performed. An increase from 1-2% of cells staining positive for β-galactosidase among
siGFP control cells to 8-10% positive cells in siRNA to CYP33 was observed (Fig. 17).
Shown below are representative fields (Fig. 17).
Density of nucleosomes depends on CYP33 levels in MSA cells
CYP33 over-expression leads to no change or a slight increase in the H3 ChIP
signal at the promoters of the MLL target genes CDNK1B and MYC, as well as at the
GAPDH promoter, whereas knockdown of CYP33 or over-expression of CYP33 M leads
to decreased histone H3 occupancy at CDNK1B, MYC, SIX1, GAPDH, and ACTIN. This
is possibly due to a dominant negative effect of the CYP33 mutant in which CYP33 M
competes with CYP33 for binding to MLL target gene promoters. The H3 ChIP signal is
a surrogate for nucleosome occupancy. Nucleosomes can either be displaced from
promoters, by ATP dependent nucleosome remodeling complexes, or upon rounds of cell
division can be replaced due to increased activity of gene transcription. CYP33 over-
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Figure 17. Knockdown of CYP33 leads to an increase in the senescence marker SA
β-galactosidase.
Twenty-four hours after knocking down CYP33 using two separate siRNAs
(CYP33(1) or CYP33(2) and using siGFP as a control, cells were incubated and treated
with X-Gal as a substrate to examine senescence-associated β-galactosidase (SA βgalactosidase). Ten fields were counted for cells that were positive or negative for
staining with X-Gal. The percent population staining positive is shown in the graph. The
error bars are standard deviation from the ten fields tested. Arrows point to cells that
stained positive.
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Figure 18. H3 levels at MLL target gene promoters change upon CYP33
knockdown, or CYP33 M over-expression.
After transfection of various plasmids as described in Figure 6, ChIP was
conducted in order to determine Histone H3 levels as a surrogate marker for nucleosome
density. Each transfection was normalized first to Input, and then vector control (siGFP,
or pCEP4) was set as 1. An antibody directed against mouse IgG was used as a negative
control, but is not shown. A) CYP33 knockdown using siRNA. B) CYP33 or CYP33 M
over-expression in MSA cells. Shown is a representative of three experiments.
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expression does increase H3 levels at the SIX1 and ACTIN gene promoters. When
comparing the effects of CYP33 to CYP33 M over-expression, there is a significant
change in H3 levels at all gene promoters tested (Fig. 18).
Expression of housekeeping genes changes upon CYP33 knockdown or overexpression
In order to accurately measure the mRNA levels traditionally reference genes like
GAPDH and ACTIN are used. However, the standard reference genes GAPDH and
ACTIN both changed more than four fold over many different experiments (Fig. 19) after
over-expression or knockdown of CYP33. Other standard reference genes described in
the literature were tested (Chen, D 2011). Transcription of a panel of reference genes,
TCBP, RNU47, RNU48, GAPDH, and ACTIN, also showed variations upon either CYP33
over-expression or knockdown (Fig. 19) (Chen, D 2011). Beta 2 microglobulin (B2M), a
commonly used reference gene, was also tested. B2M, an MHC class I molecule, upon
CYP33 over-expression showed the smallest variation and was consequently used as the
reference gene in this study (Fig. 19).
In addition to changes in CDNK1B and MYC gene expression, the mRNA levels
of MLL target genes, ACTIN and GAPDH relative to B2M also increases upon
knockdown of CYP33 by siRNA (Fig. 6). H3K27ac is increased at ACTIN and GAPDH
promoters, but not as much as at CDNK1B, MYC, or SIX1 promoters, and the increase in
H3K27ac at GAPDH is not significant (Fig. 7). This may be due to an already high level
of H3K27ac at the ACTIN and GAPDH promoters.
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Figure 19. Various reference genes change expression upon CYP33 over-expression.
pCEP4, pCEP4-CYP33 (CYP) or pCEP4-CYP33 M (MUT) were transfected into
MSA cells. After 48 hours, cells were trypsinized and RT-PCR was conducted to
determine a reference gene that does not change upon CYP33 overexpression in MSA
cells. Shown is the Ct (cycle threshold value) of the vector control, and how CYP33
leads to an increase or decrease of the cycle threshold. The error bar represents
plus/minus standard deviations from triplicate PCRs.
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Figure 20. HOXC8 expression is increased upon 5-Azacytadine treatment in MSA
cells.
A) A kill curve for MSA cells using various concentrations of 5-Azacytadine (5Aza). Various conentrations of 5-Aza were used. For concentrations above 5uM of
treatment with 5-Aza cells detached from the plate and stopped cellular
growth/proliferation. B) Mock (EtOH), CsA (Cyclosporin A), UNT (untreated), or 5Aza, a DNMT methylatransferase inhibitor, was used to treat MSA cells every 24 hrs. for
72 hrs. After 72 hrs., cells were harvested for RNA, and real-time RT PCR was
performed.
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HOX genes such as HOXA9 could not be used as genes to study the effect of knocking
down CYP33 as in the MSA cell line since HOX genes remained silent even after CYP33
knockdown in these cells. Consequently, since no gene expression was detected upon
knockdown of CYP33, it was hypothesized that HOX genes could be silenced by other
mechanisms independent of histone modifications, such as DNA methylation. In order to
test if the HOX gene cluster was silenced by DNA methylation, the cells were treated
with 5-azacytadine (5-Aza), a DNMT (DNA methyltransferase) inhibitor. A kill curve
showed that treating MSA cells with concentrations of 5-Aza above 5μM caused cells to
detach from the plate, round up and stop proliferating (Fig. 20). Concentrations of 5μM,
500nM, and 250nM were used. Cells were treated for 72 hours in medium plus EtOH
(vehicle) or 5-Aza. Due to the short half-life of the inhibitor every 24 hours the media
along with EtOH or 5-Aza was replaced. After 72 hours, cells were harvested, RNA was
collected, and real time RT PCR was performed. Compared to controls, HOXC8 mRNA
levels increased in MSA cells treated with 5-Aza suggesting that DNA methylation
inhibits HOXC8 gene transcription in MSA cells(Fig. 20).

CYP33 is recruited to MLL target gene promoters when MLL is present in the cells
Mouse Embryonic Fibroblasts (MEFs) that either contain WT MLL protein (MEF
MLL+/+), or possessing a truncated MLL in which LacZ is fused to MLL in-frame within
Exon 3 of MLL (MEF MLL-/-), were used to test whether CYP33 is recruited to the
promoter of MLL target genes in an MLL-dependent manner (Yu, B 1995). MLL-/- is

98

CYP33 ChIP

0.800%
0.600%

0.400%

MEF-/-

MEF+/+

5
4
3
2
1

HoxA9

Cdkn1b

MEF-/-

MEF+/+

MEF-/-

0
MEF+/+

MEF-/-

C

MEF-/-

B

Cdkn1b

MEF+/+

Myc

Fold change in mRNA gene
expression

HoxA9

MEF+/+

0.000%

MEF-/-

0.200%
MEF+/+

Percent INP

A

Myc

Figure 21. CYP33 is recruited to chromatin in MLL+/+ MEFs but not in MLL-/MEFs.
A) Either mouse IgG or α-CYP33 antibody was used for ChIP in cells that have
wild-type (WT) MLL (MLL+/+) or MLL in which a LacZ construct is inserted into Exon
3 (Yu, B 1995) and produces a protein lacking both a PHD finger and a SET domain.
Such cells are MLL-null (MEF-/-). ChIP for CYP33 binding at Myc, HoxA9 and Cdkn1b
gene promoters. Percent input is shown. B) A Western Blot for CYP33 is shown for the
ChIP to demonstrate that CYP33 is expressed at equal levels in the two cell lines. C)
mRNA expression of MLL target genes are shown in MLL+/+ or MEF-/-. Shown is a
representative of two experiments.
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devoid of the ability to bind CYP33 or activate MLL target genes. As mentioned above,
CYP33 binds to MLL through the former’s RRM domain. The RRM domain also has the
ability to bind to RNA (Mi, H 1996, Hom, R 2010). It is therefore possible that CYP33
can be recruited to chromatin through RNA, independently of MLL.
In order to test the hypothesis that CYP33 recruitment to chromatin is mediated
by MLL, ChIP was conducted in MLL+/+ MEFs and MLL-/- MEFs to determine whether
CYP33 can still be recruited to the chromatin in cells lacking MLL. There is no
recruitment of CYP33 to chromatin in MLL-/- MEFs, supporting the hypothesis that
CYP33 binds to chromatin through MLL as opposed to recruitment to chromatin through
RNA (Fig. 21). Shown by Western Blot, CYP33 was still expressed at similar levels in
MEF-/- MEF showing that loss of recruitment of CYP33 at MLL target gene promoters is
not due to a lower concentration of CYP33 protein within MLL-/- MEFs (Fig. 21B). This
is especially necessary as a control because in this study we found evidence that CYP33
may auto-regulate its own gene expression (Figs. 21, 22). HoxA9, Cdnk1b, and Myc are
transcribed in MLL-/- MEFs, but CYP33 does not bind to their promoters. The lack of
CYP33 binding to these promoters in MLL-/- MEFs is not due to silencing of gene
transcription. In MLL-/- MEFs, Myc mRNA is higher when compared to MLL+/+ MEFs
(Fig. 21C). In MLL-/- MEFs, both HoxA9 and Cdnk1b were shown to produce mRNA
gene transcripts, albeit at a reduced level in comparison to MLL+/+ MEFs (Fig. 21C).
Hence, these data support the hypothesis that CYP33 is recruited to MLL target genes by
MLL or via an MLL-dependent mechanism.
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Figure 22. CYP33 is recruited to the promoter of various genes in MSA cells.
ChIP for CYP33 recruitment to MLL target gene promoters, CDNK1B, MYC,
CYP33, and to housekeeping genes such as ACTIN and GAPDH in MSA cells. IgG is
used as a control for non-specific interactions. Percent input is shown for CYP33 or IgG
ChIP. Representative of two independent experiments is shown. Error bars are standard
deviations from triplicate real time PCR reactions.
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To study CYP33 and MLL target gene promoters in the human system, the MSA
cell line was used. The MSA cell line is a thyroid carcinoma-derived cell line in which
the 5’-HOX genes are silenced. CDNK1B, SIX1, and MYC genes whose promoters are
established MLL targets were studied along with CYP33 and MLL promoters for CYP33
recruitment. CYP33 binds to CDNK1B, SIX1, MYC, CYP33 and MLL promoters in the
MSA cells as shown by ChIP (Fig. 22). CYP33 is recruited to MLL target genes in both
murine and human cell lines, and in MEFs it does so in a MLL-dependent manner. It is
important for understanding the knockdown and over-expression studies that were
conducted in this study to show that CYP33 is recruited at MLL target genes in MSA and
MEF cell lines.
In order to test whether the PPIase activity of CYP33 was responsible for the
increase in MLL target genes observed after the knockdown of CYP33, Cyclosporin A
(CsA) was used to inhibit the PPIase activity of cyclophilins. MLL target gene
expression was determined by real time PCR. MEF cells were treated for 96 hours with
EtOH or either 5μM or 10μM CsA. When inhibiting CYP33 with CsA, only in WT MEF
cells is expression of Mll target genes Cdnk1b, HoxA9, Myc, as well as the Myc target
gene Cdkn1a increased (Fig. 23). For Cdkn1a and Cdnk1b, an additional increase is seen
for 10μM versus 5μM. Therefore, the response observed was dose-dependent.
In the MLL null MEFs, inhibition of CYP33 using up to 10uM CsA did not lead
to an increase of MLL target gene expression (Fig. 23). These results support the
previously tested hypothesis that CYP33 effects on Mll target genes are dependent on
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Mll. Several previously reported MLL target genes, HoxA9, Myc, Cdnk1b, were tested.
Cyp33, and Mll, which are not known to be MLL target genes, were also tested as these
were shown to have recruitment of CYP33. Cdnk1a is regulated by Myc and its mRNA
levels increase upon CsA treatment. Cdnk1a and Cdnk1b, the expression of which may
lead to cellular senescence (Alexander, K 2001), will be discussed in greater detail below.
As mentioned above, CYP33 is not recruited to the chromatin in the absence of MLL
(Fig. 21). Thus it can be inferred that CYP33 must bind to MLL in order to exert its
repressive effects and the absence of MLL negates any of the repressive effects
attributable to CYP33.
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Figure 23. Upon treatment with CsA, expression of MLL, CYP33 and MLL target
genes is increased in MEF+/+ but not MEF-/-.
MEF+/+ or MEF-/- cells were treated for 96 hours with either EtOH (control) or
10μM CsA. Twenty four hours after treatment cells were typsinized and plated at a lower
density in order to avoid confluency. After 96 hours, RNA was collected and real-time
PCR was performed. A) Mll, Cyp33, c-Myc, Cdnk1a, Cdnk1b, and HoxA9 before and
after treatment with CsA in MEF+/+. B) Mll, Cyp33, c-Myc, Cdnk1b, and HoxA9 before
and after treatment with CsA in MEF-/-. Error Bars derived from standard deviations
from triplicate real-time PCRs. A representative of two independent experiments is
shown.

.

CHAPTER V
DISCUSSION

It has been proposed that CYP33 functions to recruit HDAC1 to chromatin in
order to repress MLL target genes (Wang Q, 2011; Xia Z, 2003). CYP33 or CYP33 M
was over-expressed to determine if HDAC1 or BMI1 were recruited to MLL in a CYP33
PPIase dependent manner. Prior to this study, it was hypothesized that CYP33 would
lead to an increase in HDAC1, a reduction in H3K27ac, and an increase in PRC2 binding
to MLL target genes, such as CDNK1B and MYC (Fig. 24). This would allow PRC2 to
trimethylate H3K27, resulting in gene silencing. Upon knockdown of CYP33 by siRNA
the opposite would be hypothesized to occur. PRC2 binding to target genes decreases
and an increase in H3K27ac and H3K4me3 would be observed. This suggests a
reduction in HDAC1 recruitment and the ability of the SET domain of MLL to methylate
H3K4 and of the MLL-associated CBP to acetylate the histones at MLL promoters;
acetylation of H3K27 would prevent its methylation by the PRC2 complex (Tie F, 2009;
Pasini D, 2010; Jung H, 2010) (Fig. 24).
CYP33 decreases H3K27ac at MLL target genes upon CYP33 over-expression
MLL regulates the expression of many transcription factors and cell cycle
regulators which are determinants of cell fate. This study focused on the molecular
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Figure 24. Working model of CYP33-mediated gene repression mechanism.
It was hypothesized that following over-expression of CYP33, HDAC1, BM11,
hPC2, and CtBP would be recruited to the RD of MLL in a PPIase-dependent manner
(upper left). This would lead to repression of gene transcription by reducing H3ac levels,
including H3K27ac. PRC2 then could methylate H3K7me3 (upper left). Upon overexpression of CYP33-M (PPiase mutant), HDAC1 is no longer recruited to the chromatin
(upper right). Upon knockdown of CYP33 or inhibition by CsA, HDAC would be
removed; the HAT activity of CBP would be restored, leading to histone acetylation
followed by increased gene expression (lower right).
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mechanism of down-regulation of select MLL target genes, CDNK1B, MYC, and SIX1,
by CYP33 and MLL (Wang Q, 2011; Wang P, 2009; Milne T, 2005). Although previous
studies determined the critical residues that are important for the interaction between
CYP33 and MLL in vitro, the mechanism behind the down-regulation of MLL target
genes has yet to be elucidated (Wang Z, 2010; Park S, 2010). CYP33 has been shown to
be an important negative regulator of MLL activity and is dependent upon HDAC
activity for its repressive function, as tricostatin A prevents repression of MLL target
genes in cells over-expressing CYP33 (Anderson M, 2001; Fair K, 2002; Wang Z, 2010;
Park S, 2010).
CYP33 has been previously shown to regulate H3ac (K9ac and K14ac) and
H3K4me3 (Park S, 2010; Wang Z, 2010). Upon over-expression of CYP33, but not of a
CYP33 PPIase mutant, H3ac decreases at HOXC8 and HOXA9 promoters and H3K4me3
is reduced at CDKN1B and HOXC8 (Park S, 2010; Wang Z, 2010). The H3K27 status
was not examined in these studies. H3K27ac along with H3K9 and H3K14 acetylation is
found at the promoters of active genes (Kurdistani S, 2004). H3K27ac is preferentially
located at genes that are actively transcribed and, along with H3K4me1, at active
enhancers ( Rada-Iglesias A, 2011; Pekowska A, 2011; Melgar F, 2011; Creyghton M,
2010). In this study, H3K27ac was analyzed and found to be decreased at the CDNK1B,
MYC, and SIX1 promoters upon CYP33 over-expression. CYP33-M overexpression did
not result in decreased H3K27ac at the promoters of MLL target genes, which implies
that the decrease in acetylation is dependent on the PPIase activity of CYP33. H3ac
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(H3K9 and H3K14) levels, did not change in a CYP33 PPIase dependent manner, but
tended to decrease upon CYP33 or CYP33-M overexpression. Conversely, upon
knockdown of CYP33, H3ac levels (including H3K27ac) are increased at a number of
known MLL-regulated genes such as CDNK1B, MYC, and SIX1. ACTIN and GAPDH,
two housekeeping genes which were also tested, showed similar upregulation to the
known MLL target genes. Upon over-expression of CYP33 in MSA cells, only H3K27ac
correlated with transcriptional mRNA levels; changes in H3K9 and H3K14 acetylation
levels did not. Upon knockdown of CYP33, both H3ac and H3K27ac increased at the
MLL target genes CDNK1B, MYC and SIX1. This is in contrast to what was seen
previously upon CYP33 over-expression in which H3ac was decreased to a significant
degree. One possible explanation for the differences observed is that H3ac may be lower
than H3K27ac and H3K9 or H3K14 may not respond to HDAC1 mediated CYP33
decrease to as great a degree as H3K27. Another possible explanation is that HOX
genes, which were tested and found to decrease H3ac may respond differently to CYP33,
than MYC, SIX1 and P27. This is feasible as in Park et al, upon CYP33 over-expression
HOXC8 decreased H3ac, whereas at the P27 promoter H3ac did not decrease (Park S,
2010; Wang Z, 2010)
Since H3K27ac decreases at CDNK1B, MYC, and SIX1 promoters after CYP33
overexpression, these studies also examined whether the H3K27me3 repressive histone
mark increased concordantly. H3K27me3 was detected at very low levels in the control
MSA cells at the CDNK1B, MYC, and SIX1 gene promoters as well as ACTIN and
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GAPDH. There also failed to be any significant differences before and after knockdown
or over-expression of CYP33. It can therefore be concluded that repression of MLL
target genes by CYP33 in the MSA cell line is not mediated by a typical PRC2-dependent
mechanism as was first hypothesized (Fig. 24). Although this does not exclude the
possibility that H3K27me3 were already at their minimal levels and upon CYP33
knockdown could not be reduced further. Also it may take longer to deposit H3K27me3,
after the HDAC1 has removed the acetyl mark from H3K27. Therefore upon a more
sustained level of CYP33 over-expression for a longer time, H3K27me3 may be
regulated by CYP33. Alternatively, this study does not exclude that CYP33 may play a
role in mediating PRC2 deposition of H3K27me3 in other cells lines or in other target
genes within MSA cells. It only shows that in the MSA cell line, at the MLL gene
promoters tested, H3K27me3 is not regulated by CYP33.
The methylation of H3K27me3 by Ezh2 in the PRC2 complex may be misregulated or blocked in the MSA cell line, as Ezh2 was bound at the MLL target gene
promoters in these cells, although there is little H3K27me3 present at MLL target genes
(this study). Mis-regulation of Ezh2 has been previously shown, as in many cancer cell
lines Ezh2 is over-expressed or mutated causing a change in H3K27me3 (Hock H, 2012;
Simon C, 2012; Ernst T, 2010). Commonly believed to be an oncogene, Ezh2, has also
been suggested to function as a tumor suppressor in myeloid malignancies, such as MDS
and T-ALL (Nikoloski G, 2010; Ntziachristos P; 2012).
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BMI1 and HDAC1 are recruited to the MLL-RD in a PPIase dependent manner
Previously it was shown that over-expression of CYP33 leads to increased
recruitment of HDAC1 to the RD of MLL (Xia, Z 2003). In the current study, CYP33
over-expression was shown to lead to increased recruitment of both HDAC1 and the
polycomb group protein BMI1 to MLL-N. Over-expression of CYP33-M, which lacks
PPIase activity, failed to increase recruitment of HDAC1 or BMI1 to the RD of MLL-N.
Two separate constructs encoding MLL-N (amino acids 1-2665) and a MLL RD-PHD
peptide (amino acids 1088-1371,1394-1630) which contains the RD and PHD finger 1-3
cluster, but lacks the bromodomain were used in order to determine if the binding of
HDAC1 and BMI1 to the MLL-RD depended on other domains besides the MLL-RD and
the MLL PHD3, upon CYP33 or CYP33 M overexpression.
An immunoblot for HA shows that HA-CYP33 and HA-CYP33 M are similarly
recruited to MLL-N (Fig 10). This is in contrast to what was shown in vitro by Wang et
al. (2010). These investigators reported that a PPIase deficient mutant of CYP33 cannot
bind a cassette containing the MLL PHD3 and bromodomain, and that the CYP33-RRM
domain alone does not bind to the PHD-Bromodomain cassette due to the lack of PPIase
activity. They hypothesize that H1628-P1629 is isomerized by CYP33 PPIase domain in
order to enact a conformational change between the PHD3 and bromodomains. This then
will allow for CYP33 to bind. There are a couple of reasons why CYP33 M
overexpressed in living cells may be able to bind to the MLL-N PHD3 whereas in vitro it
is unable to do so. 1) The complex composition between an in-vitro experiment and an
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experiment conducted within cell culture may open the bromodomain rendering the
PPIase activity of CYP33 unnecessary for the RRM of CYP33 to bind to the PHD3 of
MLL-N. 2) Another cyclophilin, such as CYPA may be able to provide the necessary
PPIase activity. Our results imply that the PPIase dependence of HDAC or BMI1
binding to MLL-N, is not explained by differences in CYP33 recruitment to the MLL
PHD3.
HDAC1 recruitment to the MLL RD showed dependence on the PPIase activity in
both MLL-N and MLL RD-PHD constructs. This suggests that the PPIase target
regulating recruitment of HDAC1 is within either the MLL RD-PHD finger construct,
HDAC1 itself, or histone H3. BMI1 recruitment on the other hand, unlike HDAC1,
shows a difference in its recruitment between the MLL-N and the MLL RD-PHD
construct. Increased binding of BMI1 to the MLL RD-PHD construct no longer depends
upon the PPIase activity of CYP33. This suggests that another property of CYP33 aside
from its PPIase activity is necessary to promote BMI1 recruitment. CYP33 contains other
domains besides the cyclophilin domain: the RRM and the conserved spacer, which may
function to promote recruitment of BMI1 to the MLL RD-PHD finger construct. In
addition, the cyclophilin domain may have a function separate from its enzymatic activity
that helps bring BMI1 to MLL. Nevertheless, binding of BMI1 to the full length MLL-N
requires the CYP33 PPIase activity and this requirement must involve a PPIase target,
outside the MLL amino acid sequences encompassing the RD and PHD cluster, which
can inhibit PPIase independent BMI1 recruitment. The recruitment of HDAC1 and
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BMI1 to the RD of MLL and the subsequent decrease of H3K27ac are consistent with a
model in which CYP33 regulates H3 acetylation levels by promoting recruitment of
HDAC1 to the MLL RD. The role of BMI1 recruitment is not entirely clear, and will
need further studies for its clarification.
HDAC1 and BMI1 recruitment to the chromatin does not change upon CYP33 overexpression
Due to the dependence of BMI1 and HDAC1 recruitment to MLL on CYP33 and
its PPIase activity, it was expected that HDAC1 and BMI1 recruitment to the chromatin
at MLL target gene promoters would change upon CYP33 over-expression or
knockdown. Nevertheless, the BMI1 and HDAC1 recruitment showed no increase at the
chromatin level after over-expression of CYP33 contrary to the hypothesis derived from
the Co-IP data. One possible explanation for these results is that HDAC1 and BMI1
associate with the chromatin separate from but close to MLL. Upon CYP33
overexpression HDAC1 and BMI1 bound close to MLL, through a change in
conformation in their protein complexes, through chromatin bending, or through partial
dissociation from their binding sites, are able to interact with the RD domain of MLL and
mediate gene repression at the MLL target genes. Therefore the role of CYP33 is not in
recruitment of HDAC1 and BMI1 to the chromatin but in recruitment of HDAC1 and
BMI1 to the RD of adjacent MLL.
Surprisingly, HDAC1 and BMI1 are recruited to MLL by CYP33 as shown by
CoIP, but neither HDAC1 nor BMI1 are increased upon CYP33 over-expression to the
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Figure 25. New working model for the mechanism of CYP33-mediated gene
repression.
Upon over-expression of CYP33 or CYP33 M, CYP33 binds to MLL via the
RRM domain by interacting with the PHD3 domain, as has been previously described
(Fair, K 2001, Anderson, M 2002). HDAC1 and BMI1 were shown hereinto be recruited
to MLL upon CYP33 overexpression. HDAC1 and BMI1 are bound to chromatin in
untransfected MSA cells and CYP33 or CYP33 M over-expression does not increase
binding above vector control levels. Therefore, CYP33 instead brings the already bound
HDAC1 and BMI1 into a complex with MLL through an as yet undefined mechanism.
CYP33 M, which is unable to increase HDAC1 and BMI1 recruitment because it lacks
PPIase activity, allows H3K27ac and H3ac to remain at steady state levels; thus it does
not decrease gene transcription.HDAC1 binding to chromatin is decreased. This
reconciles the observed differences between the CoIP and ChIP data.
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chromatin at MLL target genes CDNK1B, MYC, and SIX1. This suggests another model
and hypothesis (Fig. 25) in which BMI1 and HDAC1 are not soluble before being
recruited to chromatin in MSA cells but are bound to the chromatin at MLL target genes
in MSA cells at endogenous levels of CYP33. Recruitment of HDAC1 and BMI1 to the
RD of MLL occurs upon CYP33 over-expression, and only when it is in a complex with
MLL is HDAC1 able to reduce H3K27ac levels, perhaps through the inhibition of MLLassociated CBP HAT activity. Upon knockdown at specific genes, CDNK1B and MYC,
HDAC1 binding to chromatin is decreased. This reconciles the observed differences
between the CoIP and ChIP data, but leads to additional hypothesis that need to be tested.
Knockdown of CYP33 by siRNA or inhibition of CYP33 by CsA leads to oscillations
in gene transcription
Due to the oscillations seen in MSA cells for CYP33 mRNA gene transcription as
measured using mRNA steady-state levels, it was hypothesized that CYP33 and MLL
might be part of a negative feedback loop. In conducting ChIP at the CYP33 promoter in
MSA cells or MEFs, it was found that CYP33 binds at the chromatin of the CYP33
promoter, supporting the hypothesis of regulation of the CYP33 gene by CYP33 and
MLL. Therefore CYP33 through MLL may participate in a negative feedback loop that
would be the cause of the oscillations observed upon CYP33 knockdown. The simplest
feedback loop within this context would be the MLL protein transactivating the CYP33
gene, leading to an increased level of CYP33 protein, which inhibits MLL transactivating
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Figure 26. CYP33 recruitment to the CYP33 promoter and oscillations of CYP33
mRNA transcripts upon CYP33 knockdown suggests the existence of a negative
feedback loop regulating the expression of CYP33.
As diagramed above, the negative feedback loop involving CYP33 may involve
the MLL protein regulating the transcription of the CYP33 gene. Therefore upon CYP33
knockdown with siRNA, MLL can then lead to increased levels of CYP33 mRNA. This
leads to increased CYP33 protein levels, which then inhibit CYP33 transcription.
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activity on the CYP33 promoter (Fig. 26). The oscillations in CYP33 levels in turn
produce oscillations in the expression of MLL-regulated genes, as well as in the
expression of several housekeeping genes which are not known MLL targets (see section
on housekeeping genes below).
Circadian rhythms are natural oscillations that also may contribute to CYP33 and
MLL-mediated oscillations. It was recently discovered that MLL regulates circadian
rhythm function by regulating the transcription of the CLOCK and BMAL1 genes (Katada
S, 2010). CLOCK and BMAL1 proteins function in a series of feedback loops to
regulate genes involved in synchronizing the light/dark daily cycle with the mammalian
cell functions. Circadian rhythm disruption is increasingly being found to be linked to
cancer (Sahar S, 2009). This may contribute to natural oscillations within cancer cells
that may go undetected in many studies. The period of oscillation caused by CYP33 is
much longer than the 24 hour circadian period, and they are more likely caused by a
separate negative feedback loop.
Modulation of CYP33 leads to changes in cell proliferation and senescence
MSA cells were found to be reliant on CYP33 for proliferation. Since both
overexpression and knockdown of MLL led to a slowdown of cell growth by inhibition
of the cell cycle (Liu H, 2007; Mishra B, 2009), it was not surprising that CYP33 also led
to a decrease in cell proliferation/growth. CYP33 over-expression or knockdown led to a
decrease in cell doubling time in MSA cells. Although no obvious cell cycle inhibition
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was seen using FACS analysis of propidium iodide stained cells, a more comprehensive
study needs to be conducted to dissect the role of CYP33 in cell cycle regulation.
CYP33 over-expression led to decreased cellular ATP levels while overexpression of CYP33-M resulted in ATP levels similar to ones of the vector control.
Knocking down CYP33 did not lead to increased PI staining of living cells, an indicator
of apoptosis. ATP levels were also unchanged. An increase in SA β-galactosidase
activity was observed after CYP33 knockdown in MSA cells, compared to siGFP
controls. This suggests that CYP33 at control levels may function to prevent senescence
in MSA cells. The increase in senescence could be due to the increase in CDKN1A and
CDNK1B expression that is seen upon CYP33 knockdown (Fig 14,15,23).
CYP33 affects nucleosome density within MSA cells
CYP33 does not only affect H3K27ac levels but also affects the H3 levels within
target gene promoters, potentially reflecting nucleosome density at these sites. Reduction
in H3 levels could also represent a reduced ability of the H3 antibody to bind to the
histone tail; this is known as epitope masking. Upon knockdown of CYP33, H3 levels
decreased, and when comparing the effect of over-expression of CYP33 or CYP33 M, the
density of nucleosomes after CYP33 overexpression was always higher than that seen
with CYP33-M overexpression (Fig. 14). MLL interacts with the SWI/SNF chromatin
remodeling complex, yet the functional consequences of this interaction have not been
elucidated (Rozenblatt–Rosen O, 1998). It is conceivable that the CYP33-MLL complex
functions to regulate chromatin remodeling at MLL target genes, leading to decreased
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nucleosome occupancy at MLL promoters. This hypothesis could be tested by
performing nucleosome remodeling assays in the presence and absence of CYP33
(Jaskelioff M, 2009).
All chromatin marks in this study were normalized to histone H3. Normalization
allows for one to look at changes in histone modifications versus changes in the
nucleosome density or epitope masking. This allows for a better comparison between
two groups that have been differentially treated. In this study when looking at CYP33 or
CYP33 M, and siGFP or siCYP33, H3 was used to normalize the marks between the two
groups.
Housekeeping genes ACTIN and GAPDH are also regulated by CYP33
Surprisingly, ACTIN and GAPDH transcription were up-regulated after CYP33
knockdown, and decreased after CYP33 overexpression (Fig 7). Concordant with
increased transcription H3K27ac and H3ac increased at the promoter of ACTIN upon
CYP33 knockdown in MSA cells. H3K27ac at the ACTIN and GAPDH promoters were
also found to be decreased after CYP33 over-expression (Fig. 8).
CYP33 binds to known MLL target genes such as CDNK1B and MYC, and it was
found through ChIP that CYP33 binds to β-ACTIN, GAPDH, and B2M promoters. In
addition to an increase in mRNA upon CYP33 knockdown, ACTIN and GAPDH
followed a similar pattern to the MLL target genes p27, MYC, and SIX1 in that H3K27ac
and H3ac changed according to the mRNA levels within cells. It has been shown that
MLL binds to housekeeping gene promoters during mitosis and that MLL is necessary to
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allow for SET1-dependent transcription activation in the early G1 phase of the cell cycle
(Blobel G, 2009). Therefore, it is possible that CYP33 regulates ACTIN and GAPDH
through MLL binding during mitosis, changing the ability of these genes to be turned on
in the G1 phase of the cell cycle.
It is possible that CYP33 could have functions that are independent of its binding
to PHD3 of MLL to regulate housekeeping genes. CYP33 has been found to bind to
RNA as well as to both a XAB2 protein complex with function in transcription coupled
excision repair and in alternative splicing, and in the large spliceosome protein complex
(Kuraoka I, 2008; Mesa A, 2008). XAB2 has been shown to bind to the RRM domain of
CYP33 through tetratricopeptide repeats (TTPR) (Kuraoka I, 2008). Because of the
involvement of CYP33 in these complexes it has been hypothesized that it may play a
role in alternative splicing, but this has not been tested as yet. It is possible that CYP33
bind other proteins with TTPRs mediating its MLL-independent functions (Kuraoka I,
2008).
The molecular mechanism by which MLL regulates the reactivation of mitotic
genes remains unclear. In mitotic chromatin at MLL target genes, H3K4me3 levels are
similar in both control and MLL-knockdown cells. This suggests that the mechanism of
MLL regulation of mitotic chromatin is independent of the MLL methyltransferase
activity. The proposed function of MLL is to tether key co-regulatory proteins, WDR5,
RbBP5, or ASH2L to active gene promoters while they are transiently silenced in mitotic

120
chromatin (Blobel G, 2009). Blobel et al. propose that MLL acts as a placeholder for the
HMT SET1 complex that is displaced during mitosis (Blobel G, 2009).
General Conclusions
CYP33 has been previously thought to be recruited to MLL target gene promoters
by interaction with the PHD3 of MLL. This study shows that CYP33 is recruited to the
promoters of MLL target genes like HOXA9, MYC, and CDKN1B, through an MLL
dependent mechanism, since in the absence of MLL, CYP33 is not recruited to these
target gene promoters.
CYP33 overexpression leads to recruitment of HDAC1 and BMI1 to the RD of
MLL in a CYP33 PPIase dependent manner. HDAC1 was previously shown to bind
MLL in a PPIase dependent manner using CsA (Koonce, M 2004). As CsA is a general
inhibitor of all cyclophilin family PPIase's, in this study we used a CYP33 PPIase mutant
lacking cis-trans prolyl isomerase activity (CYP33-M). Using a CYP33mutant deficient
in PPIase activity, we showed that it is the PPIase of CYP33 that is important for HDAC1
recruitment and extended the previous studies to include another important co-repressor,
BMI1, showing that CYP33 regulates BMI1 recruitment to MLL as well.
However, the binding of HDAC1 and BMI1 to MLL does not lead to a similar
increase in recruitment of these co-repressors to chromatin at the MLL target gene
promoters, since upon CYP33, or CYP33 M overexpression HDAC1 and BMI1
recruitment to the chromatin is unchanged.
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It has been shown that H3Ac (H3K9ac and H3K14ac) is decreased upon CYP33
over-expression (Wang Z, 2010). In this study H3K27ac, as a mark of activation, was
also studied in addition to H3ac. CYP33 over-expression or knockdown leads to changes
in H3K27ac, and knockdown of CYP33 leads to a marked increase of H3ac and
H3K27ac marks at MLL gene promoters. Decreased H3K27ac at the promoters of MLL
target genes, CDNK1B, MYC, and SIX1 leads to a decrease in mRNA gene expression
(Park S, 2010; this study).
The initial hypothesis of this study was that H3K27ac prevents H3K27me3 and
upon over-expression of CYP33, H3K27ac would decrease, and H3K27me3 would
increase. In the MSA cell line at the MLL promoters studied this turned out not to be the
case as H3K27me3 was very low and remained unchanged after CYP33 over-expression
or knockdown. So, gene repression after CYP33 overexpression does not depend on
H3K27 methylation.
It was observed in this study that CYP33 inhibition by CsA, or its knockdown by
siRNA, leads to oscillations of MLL target gene expression. The levels of MYC, BMI1,
CDKN1A, and CDKN1B mRNAs were all shown to oscillate. Expression of CYP33 and
MLL was also shown to oscillate upon knockdown or CsA inhibition by CYP33.
CYP33 was also shown to bind to the CYP33 gene promoter by ChIP in MSA and
MEFs cells (Fig. 21, 22). These two observations suggest that a regulatory negative
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feedback loop exists, involving the CYP33 gene promoter, and the MLL protein, through
which CYP33 regulates its own gene transcription.
Understanding the functions of the co-regulators of MLL such as HDAC1, BMI1,
and CYP33 is important for gaining further insight into the regulation of MLL and MLLfusion leukemias. By studying CYP33, which is a critical regulator of MLL, a better
understanding of the molecular functions of MLL and MLL-fusions is possible.
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